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Thesis abstract 
 
Cancer is the second leading cause of death in the world and melanoma is the deadliest type 
of skin cancer. Although surgery, radiotherapy and chemotherapy are still standard treatments, the 
discovery of the role played by the immune system in cancer has allowed the development of new 
treatments, called immunotherapies. The goal of these treatments is to help the immune system 
eradicate cancerous cells, for example by increasing the anti-tumor response of the patient. 
 
In this particular case, the treatment has to activate cytotoxic CD8+ and CD4+ helper T cells 
against the cancer cells. This can be done by using subunit vaccines composed of tumor antigens, 
adjuvants and a delivery system, which will be internalized by dendritic cells (DCs). The vaccine 
induces the activation of DCs followed by their migration to the lymph nodes, where they will 
educate T cells against specific antigens. Our laboratory has developed two different delivery 
systems, nanoparticles (NPs) and polymersomes (PSs) that can enhance the vaccine’s immune 
response by efficiently entering the lymphatic system, due to their size, and drain to the lymph 
node. Once they reach that location, they will be internalized by DCs and induce an anti-tumor 
response. 
 
In this thesis, we used these two nanocarriers to create a vaccine composed of different nano-
adjuvants capable of activating several toll-like receptors simultaneously and test their efficacy at 
inducing an anti-tumor response in melanoma. We have developed and characterized the different 
nano-adjuvants, PS-MPLA, PS-CL075 and NP-CpG-B, and demonstrated, in vitro, synergistic 
effects on DC activation when PS-MPLA + PS-CL075 and PS-MPLA + NP-CpG-B were 
combined. In vivo, we showed the enhanced immune response with the different nano-adjuvant 
combinations, but only PS-MPLA + NP-CpG-B was able to delay tumor growth in melanoma. We 
then tested this vaccine in combination with radiotherapy, mimicking a clinical situation. We first 
demonstrated an enhanced immune response when combining a high irradiation dose, 15 Gy, with 
the nano-adjuvant vaccine draining the tumor-draining lymph node. Moreover, the vaccination of 
NP-CpG-B + PS-MPLA and radiotherapy increased mice survival by 17 days compared to mice 
only receiving radiotherapy. 
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Overall, we have demonstrated that combining different nano-adjuvants targeting the tumor-
draining lymph node, with radiotherapy, enhanced significantly the survival in a melanoma model. 
This approach is particularly promising since ionizing radiation is a standard treatment in cancer 
and our vaccine could be applied to a multitude of cancers since it does not contain any antigen and 
its composition can easily be modified. 
 
Keywords: Cancer, radiotherapy, vaccine, nanoparticles, polymersomes, T cells, dendritic cells, 
lymph node, toll-like receptors 
  
v 
 
Résumé de thèse 
 
Le cancer est la deuxième cause de mortalité dans le monde à ce jour, et le mélanome est la 
première cause de décès pour les cancers de la peau. Bien que la chirurgie, la radiothérapie et la 
chimiothérapie restent les traitements standards contre le cancer, la découverte du rôle central que 
joue le système immunitaire dans le cancer a permis le développement de nouveaux traitements, 
appelés immunothérapies. Ainsi, les immunothérapies ont pour but d’aider le système immunitaire 
du patient à détruire la tumeur, par exemple en améliorant la réponse immunitaire anti-tumorale du 
patient. 
 
Dans ce cas particulièrement, le traitement immunothérapeutique doit parvenir à activer des 
lymphocytes cytotoxiques CD8+ et auxiliaires CD4+ de type 1 spécifiquement contre les cellules 
tumorales. Ceci peut se faire entre autres par la création d’un vaccin sous-unité composé 
d’antigènes du cancer, d’adjuvants et d’un système de distribution adéquat. Suite à l’injection, ce 
vaccin serait internalisé par les cellules dendritiques (DCs), entraînant leur maturation, leur 
migration dans les ganglions lymphatiques et l’éducation par les DCs des lymphocytes contre les 
antigènes. Notre laboratoire a développé deux types de système de distribution visant a améliorer 
ces vaccins anti-cancer, des nanoparticules (NPs) et des polymersomes (PS), qui grâce à leurs 
tailles, sont capables d’entrer efficacement dans le système lymphatique et d’être drainées 
jusqu’aux ganglions où elles sont internalisées par des DCs. 
 
Dans cette thèse, nous utilisons ces deux technologies en combinaison pour créer des vaccins 
composés de différents nano-adjuvants, capable d’activer conjointement différents récepteurs de 
type Toll, et testons leur efficacité à induire une réponse anti-tumorale contre le mélanome. Ainsi, 
nous avons commencé par développer et caractériser les différents nano-adjuvants, PS-MPLA, PS-
CL075 et NP-CpG-B, avant de montrer, in vitro, l’utilisation combinée des différents nano-
adjuvants, notamment de PS-MPLA + NP-CpG-B et PS-MPLA + PS-CL075, pour augmenter la 
sécrétion de cytokines inflammatoires de façon synergique par les DCs. In vivo, nous avons montré 
que les combinaisons des nano-adjuvants amélioraient la réponse immunitaire, mais que seulement 
PS-MPLA + NP-CpG-B permettait de ralentir la croissance de mélanomes. Nous avons ensuite 
testé ces vaccins en combinaison avec de la radiothérapie, mimant ainsi une situation clinique. Nous 
avons démontré que la réponse immunitaire pouvait être augmentée lorsqu’une haute dose de 
radiation, 15 Gy, était combinée avec les nano-adjuvants drainant dans le même ganglion 
lymphatique que celui du mélanome. De plus, la vaccination de NP-CpG-B et PS-MPLA combinée 
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à l’irradiation a prolongé la vie des souris de 17 jours par rapport aux souris n’ayant reçu que la 
radiothérapie. 
 
Globalement, nous avons démontré que la combinaison des différents nano-adjuvants, ciblant 
le même ganglion lymphatique que la tumeur, avec la radiothérapie, prolonge de façon significative 
la durée de vie dans un modèle de mélanome. Cette approche est particulièrement prometteuse 
puisque l’irradiation est un traitement clinique standard et que notre vaccin peut être appliqué à une 
multitude de cancers du fait de sa composition et de l’absence d’antigène. 
 
Mots-clefs : Cancer, radiothérapie, vaccin, nanoparticules, polymersomes, lymphocytes T, cellule 
dendritique, ganglion lymphatique, récepteur de type Toll 
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Chapter 1 
 
Motivation, Background and Aims 
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1.1. Motivation 
 
Cancer ranks as the second leading cause of global deaths, according to the World Health 
Organization, with nearly 15% of people dying from it 1. More alarming, cancer incidence rate is 
increasing, and is expected to reach more than 20 million newly diagnosed cases per year as well as 
13 million cancer-related deaths in 2030 1,2. The causes of cancer are multiple and range from 
genetic predisposition to the life style (smoking, diet, ...), through viral infections (e.g. Human 
papilloma viruses) 2. Cancer can primarily develop in any part of the body, and often metastases to 
distant sites and organs, which dramatically increases its associated mortality 3. Among the various 
types of cancer, melanoma cancer remains the deadliest skin cancer, and is currently listed as the 
fifth and sixth most incident cancer in men and women respectively, in the United States of 
America 2. 
 
While cancer is highly heterogeneous among patients, malignant tumors share some 
biological similarities – categorized as “the hallmarks of cancer” – that help researchers to break 
down the complexity of this disease and subsequently guide the development of novel anti-cancer 
therapies. As a well-known example, cancer cells are prone to genetic mutations and 
dysregulations, allowing them to extensively proliferate independently of environmental signals or 
internal cell cycle regulation mechanisms 4. Another hallmark that has been recently adopted is the 
capability of tumor cells to evade immune destruction. Indeed, it has been demonstrated that the 
immune system is capable of both recognizing cancerous cells and mounting an anti-tumor response 
against them 5. However, this anti-cancer immune response is not sufficient to eradicate all tumor 
cells, which actively evade immune attack through different mechanisms such as the induction of an 
immunosuppressive environment with the expression of PD-L1 or CTLA-4, the secretion of anti-
inflammatory cytokines, the reduction of antigen presentation on their surface or the mutation of the 
antigen presented 6, 7. This process by which cancerous cells evade the immune system is caused by 
the anti-tumor response and is called cancer immunoediting 8. 
 
First-line treatments against cancer are mainly focused on removing the primary tumor by 
surgery, radiotherapy and chemotherapy, often used in combination with one another, with the goal 
of removing or killing as many cancer cells as possible, if not all. Radiation and chemotherapy are 
particularly prescribed to treat inoperable tumors and potential nonvisible metastasis. Over the past 
decades, an increasing number of studies showed the ability of most of these treatments to also re-
activate the immune system against cancer cells 9, 10, 11. By themselves, the induced anti-tumor 
responses are not strong enough to completely eradicate the remaining cancer cells and so, to 
increase their efficiency, immunotherapies have been added as a second-line treatment 12 . 
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Therefore, the role of an immunotherapy is to help the immune system eradicate cancer cells by 
decreasing the tumor immunosuppressive environment or increasing the anti-tumor response 13, 14. 
The current strategies used in patients to activate the immune system are to extract either dendritic 
cells or T cells from the patient and expand and activate them ex vivo before re-injecting them 
intravenously 15, 16. Another possibility, extensively studied in research as well as in clinical trials, 
is to activate the patient’s immune system in situ using cancer vaccines 17, 18. The main factors to 
consider in the development of effective cancer vaccines are the choice of antigens, adjuvants and 
the delivery system, which will influence and tune the type of anti-cancer immune response 
induced. 
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1.2. Background 
 
Over the past decade, cancer research has made a great progress in understanding the disease 
and its interactions with the immune system. From what we have learned, the success of a treatment 
will not only depend on the type of cancer, but also on the patient themselves. Indeed, since all 
tumors are different in their tumor microenvironment, cancerous cell heterogeneity and the immune 
response, the most efficient way to treat them would be through the use of personalized treatment. 
However, to understand the interplay between each patient’s immune system and their tumor, the 
discovery of tumor-specific antigens and the development of the vaccine (which safety has to be 
assessed), personalized treatment is not a viable option for the moment 19, 20. In the meantime, the 
discovery of the interaction between the tumor and the immune system opened a whole new field of 
possible cancer treatments based on the immunomodulation of the tumor, so-called immunotherapy, 
that aims at either decreasing the immunosuppressive tumor microenvironment or helping and 
educating the immune response to better fight the tumor 21. In this last case, an interesting approach 
to generate an anti-tumor response in vivo is the use of subunit cancer vaccines that would induce a 
potent immune response to eradicate tumor cells and metastasis. Such vaccines are often designed 
with three different components, namely the antigen, the adjuvant and the delivery system.  
 
Subunit cancer vaccines development 
 
Because cancer cells are derived from the self, the first obstacle in the development of a 
cancer vaccine is the choice of antigen. Indeed, antigens are either tumor-specific antigens (TSA), 
which arise from point mutation, or tumor-associated antigens (TAA), which are specifically 
overexpressed in cancerous cells but also expressed in healthy cells 22, 23. TSAs have the advantage 
of being specific to the tumor, which makes it easier to induce a specific immune response against it 
but, unfortunately, are patient-dependent and thus the identification is more troublesome24. On the 
other hand, TAAs are self-antigens and so, most reactive T cells against them have been deleted 
during the tolerance clonal selection 25. A final approach is to not define the antigen, by either using 
whole tumor lysate 26 or by inducing immunogenic cancer cell death in situ, upon radiotherapy 27 or 
chemotherapy 28, 29.  
 
Nevertheless, the development of a potent cancer vaccine does not only have to induce an 
immune response against the right tumor antigens, it also has to overcome the immunosuppressive 
environment induced by the tumor. Hence, the second parameter in the development of a cancer 
vaccine is the choice of immunomodulatory molecules, which are defined by any substance capable 
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of inducing, enhancing or suppressing an immune response, notably by influencing the signaling 
requirement between antigen-presenting cells (APCs) and T cells leading to T cell activation. 
Indeed, three signals are needed to induce the activation of T cells (Fig 1.1) 30, 31. The first one 
being the presentation of the antigen on the major-histocompatibility complex and its interaction 
with the T cell receptor on T cells 32. The second and third signals are the expression of co-
stimulatory molecules and the secretion of inflammatory molecules by APCs, respectively. The 
purpose of the last two signals is to educate T cells on the type of behavior they have to adopt 
against that specific antigen; those signals are induced by immunomodulatory molecules or 
adjuvants (i.e. any substance capable of enhancing an immune response).  
 
 
Figure 1.1 Generation of an anti-tumor response using cancer vaccines or immunostimulatory molecules. Toll-Like receptors 
agonists induce the expression of co-stimulatory molecules, in addition of cytokine secretion (not shown), which in combination with 
a tumor antigen presentation on the MHC-I, induce a T cell anti-tumor response. Figure adapted from Lizée et al.33 
 
Currently, most of the adjuvants tested in cancer vaccines are from the Toll-Like receptors 
(TLR) family, which recognize highly conserved structural motifs, known as pathogen-associated 
microbial patterns or danger-associated molecular patterns 34. The activation of the different TLRs 
will not induce the same type of immune responses, which are often classified by the phenotype of 
CD4+ T helper (Th) cells, CD8+ T cells and humoral response it induces. In the case of cancer, it is 
thought that Th1 response, with the presence of activated cytotoxic CD8+ T lymphocytes (CTL), are 
among the most effective responses for an anti-tumor immunity 35. As a consequence, all adjuvants 
known to induce this type of response have been tested in clinical trials against cancer 36. Among 
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them, the TLR-3 is an endosomal receptor that recognizes double-stranded RNA, and in the context 
of cancer, the use of synthetic agonists, Poly(I:C) and Poly (ICLC), was able to induce a potent 
tumor specific CTL, natural killers (NK) and natural killer T cells (NKT) responses 37. The TLR-4 
is present on the cell surface as well as in endosomes and is activated with lipopolysaccharides 
structures from Gram-negative bacteria and their less toxic derivatives, such as monophosphoryl 
lipid A (MPLA) or glucopyranosyl lipid A. MPLA is already approved in a prophylactic cancer 
vaccine against human papillomavirus (HPV) 38, and it is also able to induce a tumor-specific 
humoral and cellular immune response in colorectal cancer 39, 40. The third TLR targeted in cancer 
vaccines is TLR-7/8 agonist. It recognizes viral single-stranded RNA in addition to 
imidazoquinoline derivatives and its activation leads to a humoral and cellular response. A topical 
cream containing imiquimod, a small molecule, is already approved by the FDA as a therapeutic 
agent for basal carcinoma and, in addition to having a low toxicity, it is able to promote a pro-
immunogenic tumor microenvironment 41. The final TLR agonist tested for cancer vaccine in 
clinical trials activates the TLR-9 pathway when it recognizes a single-stranded DNA. It was able to 
induce an NK cell-mediated anti-tumor response in melanoma 42 and an increase in CD8+ T cells 43.  
 
Other immunostimulant molecules that do not stimulate TLRs, currently tested in clinical 
trials are anti-CD40 and IL2. The interaction of CD40, expressed by dendritic cells (DCs) with its 
ligand, is critical to induce the full activation of DCs and effective priming of T cells. Monotherapy 
of CD40-targeting antibodies in melanoma patients showed a partial response in 27% of patients 44. 
A clinical trial testing IL2 alone or in combination with an antigen, gp100, demonstrated an overall 
increase in survival in patients with melanoma 45. Interestingly, most of the clinical trials described 
above are done without using a delivery system, although it is known to be able to increase the 
immune response and decrease the risk of adverse effects. 
 
The last parameter in the development of a subunit cancer vaccine is the delivery system, 
which is as important as the other two parameters. Indeed, it can act as an immunostimulant, target 
specific organs, or cells, modify the pharmacokinetic properties of the delivered-molecule or simply 
allow the delivery of several molecules to the same location, which in other terms help tune the 
desire immune response while reducing the possible side effects. For instance, nanocarriers such as 
emulsions (MF59, Montanide), saponin based, mineral salt and virosomes particles are able to act 
per se as immunostimulatory compound. Indeed, the first three create a depot in a specific location 
whereas virosomes encapsulate the molecules of interest in an influenza virus envelope 46. Other 
types of nanocarriers such as virus-like particles, liposomes and synthetic polymeric nanoparticles 
will enhance the immune system, but not by directly interacting with it. For example, the size of the 
carrier influences their retention time in the body, where they drain and how they are internalized 
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by cells. More precisely, it was demonstrated that intradermal injection of nanoparticles ranging 
from 20-200 nm are able enter the lymphatic system and drain to the lymph with a preference for 
particles ranging around 40 nm 47, 48 whereas large ones will be retained longer at the injection site. 
In the blood stream, carriers smaller than 5 nm will be filtered by the kidney in less than 5 min or 
escape the vessel and diffuse in the local tissue, in contrast to larger nanoparticles that tend to have 
a longer circulating time but lower tissue penetration once they enter solid tumors 49. In addition, 
the uptake of the carrier by the cells through phagocytosis, macropinocytosis and receptor mediated 
endocytosis is influenced by the size, shape, surface charge and coating of the carrier 50. Briefly, 50 
nm particles are taken up quicker than larger particles but at similar size, spherical particles are 
internalized faster than nanorods, or other shape 51. The chemical structure and the approach used to 
deliver the molecule can influence the immune response by favoring different endosomal pathways; 
for instance, the molecule of interest can escape the endosomal compartment and enter the cytosol 
when coupled to the particle through a reduction, or acid, sensitive bond 52. Consequently, the 
choice of the delivery system, as well as its composition, size and shape, have to be carefully 
chosen during the development of cancer vaccines in order to induce the desired immune activation. 
 
Radiotherapy 
 
A majority of patients with solid cancer are treated with radiotherapy, alone or in combination 
with chemotherapy, making it one of the most common cancer treatments currently used 53. 
Although it is now accepted that ionizing radiation is able to induce an immune response against 
cancer cells, studies are trying to understand the effect of the dose and frequency of ionizing 
radiations on cancerous cells, the tumor microenvironment and the immune system. Currently, three 
different radiotherapy approaches are used to treat cancer: the conventional treatments are done 
with 1.8-2 Gy per fraction administered five times a week of a period of 3-7 weeks; the 
hyperfractionation treatment is delivering 0.5-2.2 Gy twice a day, 2-5 days a week and 2-4 weeks; 
and finally, the hypofractionation uses doses between 3-20 Gy administered once a day for 1-3 days 
54. Depending on the dose and the cancer, radiotherapy is able to promote immunogenic cell death 
(ICD), which massively release dead-cell associated antigens and activate the immune response 
against them, through several mechanisms (Fig.1.2) 55. 
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Figure 1.2 Radiotherapy and the induction of an anti-tumor immune response. Ionizing radiation induce immunogenic cell 
death resulting in the release of ATP and HMGB1 as well as cell surface translocation. Figure adapted from Golden et al. 56 
 
Particularly, radiotherapy treatment induces the exposure of endoplasmic reticulum chaperone 
calreticulin on the cell surface, an “Eat-me” molecule that will increase its phagocytosis by DCs 57. 
Once the DCs get activated, they enter the lymphatic system in a CCR7-dependent manner and 
drain to the tumor-draining lymph node to prime the immune response 58, 59. In addition, an increase 
in antigen-specific CTL-mediated cells lysis occurs due to an increased secretion of ATP and 
HMGB1 proteins, in the tumor 60. Although these mechanisms are not always present, T cell 
priming seems to occur in the tumor-draining lymph node when they are taking place; thus, the 
delivery of adjuvants to that location seems promising to enhance the anti-tumor response. 
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1.3. Thesis aims 
 
Over the past decade, our laboratory has developed different nanocarriers for cancer vaccines 
and demonstrated the advantage obtained when antigens or adjuvants were delivered by them. As a 
first carrier, nanoparticles (NPs), made of a polypropylene sulfide (PPS) solid core coated with a 
polyethylene glycol polymer (PEG) and ranging from 30-50 nm, were developed and conjugated to 
CpG-B 61. It was demonstrated that 5 consecutive daily injections of NP-CpG-B in the forelimb 
draining the tumor-draining lymph node decreased tumor growth compared to targeting the 
contralateral lymph node 62. Similar results were observed when NP-CpG-B was co-injected with 
NPs conjugated to tumor antigens 63. In addition, it was shown that the dose required to induce a 
strong CD8+ T cell response was lower when the vaccine was delivered by NPs compared to 
carrier-free 64. As a second material, polymersomes (PSs), formed with a bilayer of PEG-PPS 
polymer and ranging from 140-170 nm, were able to activate DCs when loaded with an adjuvant 
and an antigen 65. Interestingly, antigen delivery mediated by PSs enhanced CD4+ T cell whereas a 
stronger CD8+ T cells was detected when the antigen was loaded on NPs 66. All these studies 
successfully showed the possibility to enhance the immune response against cancer, while 
decreasing the dose. In addition, induced immune responses could be specifically tuned toward 
more CD8+ or CD4+ T cells polarized responses by the nanocarriers.  
 
However, none of these studies focused on the combined delivery of these adjuvant-
conjugated nanocarriers, although it is rationally expected that the targeting of multiple TLRs 
would increase the efficacy of the cancer vaccine 67. Moreover, we were interested in this thesis in 
testing the different vaccine formulations as a co-treatment with radiotherapy, to better mimic a 
clinical situation wherein the patient is given a standard-of-care anti-cancer treatment.  
 
Therefore, and taking advantage of the tumor-draining lymph node targeting properties 
previously demonstrated, we started this thesis by the development and characterization the 
different adjuvanted-nanocarriers (1). We then tested them in combination with one another to 
determine if synergistic effects were detected on dendritic cells activation in vitro and if this 
translated into an increase T cell immune response in vitro and in vivo, in a model of melanoma 
cancer (2). Finally, we evaluated the most promising adjuvant formulation in vivo in combination 
with radiotherapy (3). Overall, this thesis aims at developing an effective nano-adjuvant cancer 
vaccine against melanoma cancer. 
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1.4. Accomplishments 
 
The focus of the second chapter was to test the loading of four different TLR agonists to 
nanoparticles, and polymersomes, and characterize them. After synthesizing the different 
nanocarriers and polymers, MPLA or CL075 was successfully encapsulated in polymersomes 
whereas CpG-B was conjugated to nanoparticles, through a disulfide bond. The activation of bone 
marrow-derived dendritic cells (BMDCs), in vitro, was similar for NP-CpG-B compared to free 
CpG-B, as well as PS-CL075 with free CL075. A small decrease in activation was detected when 
PS-MPLA activated BMDC in comparison with MPLA only. 
 
The third chapter was focused on determining the presence of synergistic effects when our 
nano-adjuvant formulations were combined together, and if the adjuvant ratio was important for an 
enhance activation. In vitro, we observed an increase in pro-inflammatory cytokines, notably 
IL12p70 and TNF?, when combining PS-MPLA with NP-CpG-B or with PS-CL075 whereas only 
TNF? was increased for the combination of NP-CpG-B with PS-CL075. Intriguingly, the effects 
observed on BMDCs activation did not translate to the same extent on T cell activation, in vitro. 
However, in vivo, the combination of PS-MPLA with NP-CpG-B was the most efficient to reduce 
tumor growth, in the B16 model of melanoma cancer in mice. 
 
In the fourth chapter, we demonstrated an enhance T cell response after targeting the lymph 
node when combined with radiotherapy. In addition, we did not observe any difference in tumor 
growth or survival when the NP-CpG-B was injected intratumorally or intradermally, targeting the 
tumor-draining lymph node. Finally, we tested the combination of PS-MPLA + NP-CpG-B with 
radiotherapy and demonstrated an increase in survival as well as a decrease in tumor growth when 
both nano-adjuvants were co-injected. However, the T cell immune response quantification did not 
reveal any significant differences between the different vaccine formulations tested except for an 
increase in IL2 secretion after reactivation of the tumor-draining lymph node.  
 
In the final chapter, we summarized the key results of this thesis and comment on their 
implication. We also discussed the future prospect for our vaccine developed. 
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Chapter 2 
2.  
Formulation and Characterization of Adjuvant-based 
Nanocarriers 
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2.1. Abstract 
 
During the development of a vaccine, several factors are considered in order to reach a fine 
balance between its efficacy to induce a strong immune response and its safety. In the case of 
subunit vaccines, they are usually considered safe but, unfortunately, less potent at inducing an 
immune response against the antigen of interest compared to live-attenuated vaccines. Our 
laboratory has engineered two different nanocarriers capable of enhancing the immune response 
against an antigen compared to the soluble protein, which is very interesting in the case of subunit 
vaccines. Nanoparticles (NPs) have a solid hydrophobic core coated with a polyethylene glycol 
(PEG) polymer whereas polymersomes (PSs) are vesicles formed with a polymer bilayer. At first, it 
was important to understand the properties of the two nanocarriers to determine all possible 
interactions between the molecules of interest, adjuvants, and the particle. NPs either adsorb the 
molecule on its surface or covalently conjugating it by a disulfide exchange reaction. PSs, on the 
other hand, could encapsulate molecules in their vesicle or adsorb it on the polymer bilayer. We 
have demonstrated that, out of the four molecules of interest tested (Poly(I:C), MPLA, CL075, 
CpG-B), three could be successfully delivered by both nanocarriers and used for our vaccine 
formulation. In addition, they were all able to activate dendritic cells, in vitro, and induce similar 
levels of cytokine productions compared to its free counterpart. Finally, we demonstrated that both 
nanocarriers were internalized by macropinocytosis. 
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2.2. Introduction 
 
The discovery of prophylactic vaccination against infectious diseases, with live-attenuated or 
inactivated vectors, is considered one of the most groundbreaking findings in medicine 68. These 
vaccines are extremely efficient at inducing an immune response but are considered less safe than 
subunit vaccines due to the possibility for them to regain their virulence 69. In addition, in the case 
of cancer, only a few of them originate from a known pathogen and therefore subunit vaccines are 
the only possible option. Furthermore, current cancer vaccines are therapeutic rather than 
prophylactic since the antigen varies among patients, cell type and locations. Three main factors, 
such as antigens, immunomodulator compounds and delivery system, are taken into account for the 
development of an efficient CD8+ T cell subunit vaccine 70. The focus of this study was to take 
advantage of the nanocarriers developed in our laboratory to create an adjuvant-based vaccine that 
could be delivered to the tumor-draining lymph node to induce an immune response. 
 
The two different nanocarriers used for the vaccine formulation are both primarily composed 
of polyethylene glycol (PEG) and propylene sulfide but have different structures and properties 
(Fig. 2.1). The first nanocarrier, called ‘nanoparticle’ throughout this thesis, is a 30-50 nm 
polypropylene sulfide (PPS) solid core covered in an ABA pluronic F-127 triblock polymer. Due to 
their small size, they have the ability to enter the lymphatic system and go to the skin draining 
lymph node 48, 71. In addition, an enhanced delivery to dendritic cells and an increase in CD8+ T cell 
response is observed if antigens, or adjuvants, are conjugated to them 72, 73, 64. The second 
nanocarrier, called ‘polymersome’ throughout this thesis, is a 140-170 nm vesicle with a polymer 
bilayer composed of PEG17-PPS30 polymer. Although both particles are composed of the same 
components, antigens will be processed differently, inducing an increase in humoral and CD4+ T 
cell response when delivered by polymersomes versus a CD8+ T cell response for NPs 74, 66, 75. 
 
Figure 2.1 Nanocarrier structures and characteristics. Image adapted from Stano et al 10. 
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The choice of adjuvants for the vaccine was based on the feasibility to deliver them with 
nanoparticles or polymersomes and their efficacy in cancer vaccine. Toll-like receptors (TLR) are a 
subset of the pattern-recognition receptors family, which can strongly activate dendritic cells (DCs). 
They have been well studied for cancer vaccines and, in some cases, used in clinical trials. Four 
different TLR agonists, Poly(I:C), MPLA, CL075 and CpG-B, were chosen due to their properties 
to either be conjugated, adsorbed or encapsulated in particles. Poly(I:C), a double-stranded RNA, 
which is recognized by endosomal TLR-3 is present on myeloid DCs and macrophages, as well as 
cancer cells, such as colorectal, ovarian, melanoma and many others 76. The principal mechanism 
by which it produces an anti-tumor activity is by enhancing both the innate and adaptive immune 
responses 37. Many of the clinical trials involving a TLR-3 agonist are used in combination with 
pulsed peptide to treat pancreatic cancer and were able to generate antigen-specific T cells 77, 78, 79. 
The second adjuvant, MPLA, a TLR-4 agonist, is the only one signaling through the MyD88 and 
the TRIF pathways, whereas other TLRs activate either one or the other. It is mainly expressed on 
dendritic cells, macrophages, granulocyte and monocytes, as well as some cancer cells 80. MPLA is 
found in several vaccines such as a prophylactic vaccine for human papillomavirus 81, 82, allergic 
rhinitis 83, HBV 84, 85 and metastatic melanoma. The third adjuvant is a TLR-7/8, CL075, which 
signals through the MyD88 pathway and stimulates inflammatory monocyte-derived DCs 86. 
Colorectal cancer cells treated with this adjuvant showed a reduction in IL-6 production, in vitro, 
which may prevent recurrence, in addition to reducing IL-8 cytokine production in various cancer 
cell lines 87. The last adjuvant chosen (CpG-B), a TLR-9 agonist, is expressed in many different 
immune cells and activates the MyD88 pathway. In addition, our laboratory demonstrated the 
efficacy of nanoparticle conjugated CpG-B to reduce tumor growth and prolong mice survival 63. 
This adjuvant is used in several clinical trials for diseases such as HBV, Anthrax, Malaria, cancer 
and many others 88, 89. As said previously, this chapter is focused on the characterization of the 
different adjuvanted-particles and their effect on BMDC activation compared to free adjuvants. 
 
Figure 2.2 Types of Toll-Like receptors agonist used for the adjuvanted-particle formulation. 
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2.3. Materials and Methods 
Animals 
All mice used for experiments were C57BL/6 female ranging from 8-12 weeks old, purchased 
from Harlan (France) or Jax (USA). All procedures were performed in compliance with the 
Veterinary Authority of the Canton of Vaud (Switzerland) according to Swiss laws and the 
Institutional Animal Care and Use Committee at the University of Chicago (USA). 
Reagents 
Reagent grade chemicals were purchased from Sigma-Aldrich (Saint Louis, MO, USA) unless 
noted otherwise. All adjuvants, except for CpG-B, were purchased from InvivoGen (San Diego, 
CA, USA). The modified 5’SPO3-CpG-B (5’-TCCATGACGTTCCTGACGTT-3’) was purchased 
from Microsynth (Balgach, Switzerland) or TriLink Biotechnologies (San Diego, CA, USA).  
F127-COOH synthesis 
An adapted version of the protocol described by Liu et al 90 was used to synthesize the 
carboxylated F-127 from the commercially available F-127 hydroxyl polymer. Due to the 
hygroscopic nature of the pluronic, water had to be removed before starting the reaction. This was 
done by dissolving 5 g of polymer in dichloromethane (DCM) and precipitating it in diethyl ether. 
The precipitate was collected and dried overnight. The following day, 2.5 g of F-127-OH (0.2 
mmol) and 193 mg maleic anhydride (1.95 mmol) were dissolved in anhydrous toluene (10 mL). 
The solution was thoroughly degassed and the system was put under inert conditions before 500 μL 
of anhydrous pyridine (6 mmol) was added. The reaction was stirred at room temperature for 8 h, 
after which it was precipitated in cold ether and dried. A reaction yield of 64% was obtained and a 
conversion yield of 80 % was determined by 1H NMR in CDCl3. 1H NMR: ? = 1.1 (m, -CHCH3, 
PPO), 3.3 (m, -CHCH3, PPO), 3.4 (m, -CHCH2O, PPO), 3.5 (m, -CH2CH2, PEO), 4.4 (m, -COOH), 
6.3-6.5 (m, -CH=CH). 
Pyridyl disulfide cysteamine ?  HCl (PDC) synthesis 
PDC synthesis was done following the protocol from Van Der Vlies et al 61. Shortly, 3.3 g of 
Aldrithiol-2 (15 mmol) was dissolved in 10 mL of methanol before adding 570 mg of cysteamine 
?HCl (0.5 mmol) and reacting it overnight. The solution was purified twice by precipitation in 
diethyl ether before lyophilizing it and performing a 1H NMR (DMSO-d6). ? = 8.54-8.48 (m, 1H), 
8.26 (bs, 3H), 7.86-7.81 (m, 1H), 7.75 (d, 1H), 7.33-7.23 (m, 1H), 3.12-3.03 (m, 4H). The reaction 
and conversion yield obtained were 80% and 100%, respectively. 
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Nanoparticle formation 
The synthesis was adapted from the protocol described by Rehor et al 91. Briefly, 500 mg, at a 
3:1 ratio of hydroxyl to carboxyl polymer, F-127 pluronic, was dissolved in 10 mL mQ H2O before 
purging and degassing the system with argon (Ar). Afterwards, 400 μL of propylene sulfide (5 
mmol) was added to the reaction and stirred for 30 min to create the emulsion. In the meantime, 
14.8 mg of four-arm initiator (0.024 mmol, synthesized in the laboratory) was dissolved, and 
activated with a solution of 0.5 M NaOCH3, in MeOH, before adding it to the reaction flask. After 
stirring for 15 min, 60 μL of 1,8.Diazabicyclo[5.4.0]undec-7-ene (DBU) was added before flushing 
the reaction with Ar and leaving the polymerization go overnight. The following day, the solution 
was exposed to air for 2 h in order to cross-link the nanoparticle core before quenching the 
remaining surface thiolates with 47.5 mg iodoacetamide (0.26 mmol) for 30 minutes. An Ellman’s 
assay was performed to determine the presence of thiolates in the solution, following the 
manufacturer’s indications (ThermoFisher scientific, Waltham, MA, USA). Nanoparticles were 
then functionalized by reacting the carboxyl groups with pyridyl disulfide cysteamine. Briefly, 2-
(N-morpholino)ethanesulfonic acid was added to the solution at a concentration of 100 mM and the 
pH was adjusted to 4 – 4.5. PDC, N-hydroxysulfosuccinimide (sulfo-NHS, Thermofisher, Waltham, 
MA, USA) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) were added to the 
nanoparticle solution at an excess of 20 equivalent relative to the amount of pluronic carboxyl 
present. The reaction was then stirred overnight before dialyzing it using a MWCO = 100 kDa for 2 
days. After filtering the solution (0.22 μm filter, Millipore Corporation, Burlington, MA, USA), the 
size was determined by dynamic light scattering (DLS, Nano Zs Zetasizer, Malvern, UK) and a 
small volume was lyophilized to obtain the concentration in mg/mL of material. The concentration 
of PDC was quantified by reducing a small volume with TCEP?HCl (Thermofisher, Waltham, MA, 
USA) and measuring the absorbance at 340 nm. 
Proteins or molecules conjugation to NPs 
Due to the properties of NPs, the molecule of interest can either be adsorbed on the surface of 
the nanocarrier, if it is hydrophobic, or it can react with the pyridyl disulfide group, if it has a thiol. 
In the case of OVA, the protein was dissolved at a concentration of 20 mg/mL in mQ H2O before 
adding 100 μL of it to 400 μL of NPs solution containing 6 M guanidine hydrochloride. The 
reaction was left overnight at room temperature before purifying it by size exclusion 
chromatography through sepharose CL-6B column in 1x PBS. The concentration was quantified by 
BCA assay following the manufacture’s instruction (Thermofisher, Waltham, MA, USA). Since the 
CpG-B, 5’ SPO3-CpG-B, already had a free thiol, the adjuvant was directly mixed to the NP 
solution and reacted overnight at room temperature before purifying it similarly to the OVA 
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conjugation. The quantification of the adjuvant was performed by GelRed assay (Brunschwig, 
Basel, Switzerland). Finally, due to the hydrophobicity property of MPLA, it was dissolved in 
DMSO at a concentration of 7 mg/mL before 500 μg of adjuvant was added to 400 μL nanoparticle 
solution and thoroughly vortexed. The following day, the solution was purified by size exclusion 
and quantified by HEK-BlueTM TLR-4 following the manufacturer’s protocol (Invivogen, San 
Diego, CA, USA) or by fluorescence if the adjuvant was fluorescently labeled (adjuvant was 
labeled in the laboratory).  
PEG-b-PPS diblock copolymer synthesis 
The synthesis of PEG-b-PPS polymer was adapted from Velluto et al 92, where the reaction 
was done by anionic ring opening polymerization of propylene sulfide and stopped with the 
addition of mesylated-PEG (PEG-OMs). Before starting the polymer synthesis, polyethylene glycol 
monomethyl ether (Mn 750, PEG-OH) was chemically modified with a mesylate group on the 
terminal hydroxyl group. Briefly, 15 g of PEG-OH (0.03mol) was dissolved in 200 mL of toluene 
and heated at reflux for 3 hours to remove the water using a Dean-Stark trap under inert 
atmosphere. The solution was then cooled down at 0°C before adding 11.15 mL triethylamine (80 
mmol). Afterwards, 6.2 mL methanesulfonyl chloride (82.4 mmol), diluted in toluene (Vfinal = 20 
mL), was added dropwise to the reaction under inert atmosphere. The solution was reacted for 3 h 
before removing the toluene and re-dissolving the polymer in 60 mL dichloromethane. 5 g of 
activated charcoal was added and the solution was stirred for 30 min before filtering it and 
collecting the filtrate. The polymer was then precipitated in diethyl ether at room temperature 
before adding 40 mL n-hexane and cooled at 0°C for 30 minutes. The precipitate was collected and 
dried overnight before repeating the purification step a second time. The 1H NMR in CDCl3 showed 
a 100% conversion yield and the amount recovered was 6 g (40%). 1H NMR (CDCl3): ? = 4.39-
4.36 (t, -OCH2CH2S, mesylate), 3.84-3.44 (m, -OCH2CH2, PEG), 3.38-3.36 (s, -OCH3, PEG), 3.09-
3.07 (s, -SCH3, mesylate).  
 
Once the purity of PEG-OMs was confirmed, the polymer synthesis was performed. 67.8 μL 
of benzyl mercaptan (0.58 mmol, initiator) was diluted in 6.3 mL DMF under inert atmosphere. The 
initiator was then activated with 1.3 mL of NaOMe and stirred for 15 min. The flask was then 
submerged in a water bath at room temperature before adding 1 mL propylene sulfide (12.76 
mmol). After 45 min, 940 mg PEG-OMs, dissolved in 2 mL DMF, was added to the reaction, to 
stop the polymerization, and stirred overnight. The solution was purified by precipitating twice in 
MeOH and dried before storing it at -20°C. The recovery yield obtained was 85% and the number 
of propylene sulfide monomeric unit was determined by 1H NMR. 1H NMR (CDCl3): ? = 1.26-1.32 
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(m, -CH3, PPS), 2.58-2.69(m, CH, PPS), 2.82-3.01 (m, -CH2, PPS), 3.24-4.26 (-OCH3, PEG), 3.49-
3.54 (-CH2, PEG), 7.16-7.19 (d, -CHaromat, benzyl). 
Polymersome formation 
Depending on the property of the molecule of interest, hydrophilic or hydrophobic, the 
adjuvant was added at different time points during the formulation process. If the molecule was 
hydrophobic, it was dissolved and dried with the polymer during the first step of PSs formation 
whereas if it was hydrophilic it was added during the re-hydration process. Briefly, 30-50 mg of 
PEG17-b-PPS30 was dissolved in DCM and dried in a piranha-etched HPLC glass vial overnight. 
The thin-film formed on the vial was then re-hydrated in 50 mM phosphate buffer and rotated for 3-
5 days at 4°C. The solution was extruded 5 times through a 0.2 μm nucleopore track-etched 
membranes (Whatman, Maidstone, UK). The particle size was determined by DLS, ranging 
between 140-170 nm, and a polydispersity index lower than 0.2 was obtained. Once the size was 
within the correct range, a size exclusion chromatography with Sepharose CL-6B beads was 
performed in order to separate polymersomes from unloaded molecules. The molecule of interest 
was quantified and endotoxin levels were tested by HEK-BlueTM TLR4 cells (Invivogen, San 
Diego, CA, USA) before storing the solution at 4°C for further use. 
Generation of Bone marrow-derived dendritic cells (BMDCs) 
An adapted version of the protocol described by Lutz et al 93 was used to generate CD11c+ 
BMDCs. Briefly, bone marrow cells were isolated from a C57BL/6 mouse and cultured for 9 days 
with 20 ng/mL of GM-CSF. The media was replaced with fresh media every 3 days until day 6 after 
isolation. At day 9, because 70-85% of the non-adherent cell population expresses the signature 
dendritic cell marker CD11c+, the bulk unsorted non-adherent cells were used in downstream 
studies detailed below. 
In vitro experiments 
All BMDCs activation experiments were performed in a tissue culture U-bottom 96-well plate 
and cells were used on day 9 after harvesting. All the experiments were done with 200’000 cells per 
well, plated before the different treatments were added. The adjuvant dose response experiments 
were incubated for 24 h at 37°C in a 5% CO2 incubator before collecting the supernatant and 
performing the different ELISAs.  
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The diffusion experiment under static or dynamic condition was performed as follows. 
BMDCs were incubated with either free, NP conjugated or PS encapsulated fluorescently labeled 
OVA or FITC at 37°C in a 5% CO2 incubator. At different time point, cells were collected and 
washed before quantifying the fluorescence using a plate reader spectrophotometer (Tecan, 
Männedorf, Switzerland). The plate was not mixed or moved for the static condition whereas it was 
slowly shaken for the dynamic condition. 
 
For the uptake inhibition experiments, serial dilution of filipin III (50 μg/mL), Dynasore (62.5 
μM), both in DMSO, and amiloride (500 μM), in ethanol, were prepared before cells were pre-
incubated with them for 45 min at 37°C in a 5% CO2 incubator. Afterwards, nanoparticles or 
polymersomes were added to the wells and incubated an additional 6 h at 37°C in a 5% CO2 
incubator. BMDCs were then stained and analyzed by flow cytometry.  
Flow cytometry 
Before starting the antibody staining for flow cytometry, cells were centrifuged and washed 
with 1x PBS. Afterwards, samples were incubated with a fixable live/dead stain at 4°C for 15 min 
and washed once with PBS. For surface staining, a cocktail of antibody was diluted in staining 
buffer and incubated at 4°C for 15 min, in the dark. Finally, the cells were fixed with 2% 
paraformaldehyde, washed with staining buffer and stored in the same buffer for data collection. 
Anti-mouse antibodies CD11c and MHC-II were purchased from biolegend (San Diego, CA, USA) 
whereas CD86 and live/dead fixable were from ThermoFisher Scientific (Waltham, MA, USA). 
ELISA 
Cytokine detection and quantification was performed with Ready-SET-Go! ELISA kits 
purchased from ThermoFisher Scientific and used according to the manufacturer’s instructions. 
Diffusion coefficient calculation 
The diffusion coefficients were obtained by using the Stokes - Einstein equation.  
? ? ? ????????? ? ?
????? ??????? ????
??? ??????????  
Where kB is the Boltzman constant 
????
? , T is the temperature (K), ? the viscosity 
?????
?? ?and r 
the radius of the particle (m). 
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Data collection 
Flow cytometry was performed using either a CyAnTM ADP (Beckman Coulter, Brea, CA 
USA) or a BD LSRFortessaTM (BD Biosciences, San Jose, CA, USA). The data obtained were 
analyzed with FowJo (v.10, Tree Star, Ashland, OR, USA). Graphs and statistical analysis were 
done using the GraphPad Prism 7 Software (GraphPad Software Inc, La Jolla, CA, USA). 
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2.4. Results 
Synthesis and formation of the different nanocarriers 
In order to determine if the different TLR agonists could be delivered to the targeted organ 
thanks to the vehicles developed in the laboratory, it was important to characterize their properties. 
Nanoparticles were composed of a solid hydrophobic core coated with a F-127 pluronic, at a 1:3 
ratio of F-127-COOH to F-127-OH. The synthesis of the carboxylated pluronic was performed 
under inert conditions without the presence of water and since the polymer was hygroscopic, it was 
necessary to dry it beforehand (Fig.2.3.A). The reaction and conversion yields obtained were 64% 
and 80%, respectively. Nanoparticles were formed by performing an oil-in-water emulsion at a high 
stirring speed to decrease the size of particles before polymerizing the hydrophobic core 
(Fig.2.3.B). Once NPs were formed and free thiols blocked, the carboxyl groups were 
functionalized with a pyridyl cysteamine group to be able to conjugate any thiol-containing 
molecule of interest to it. NPs ranged between 30-40 nm and the concentration of PDC varied 
between batches from 100 μM to 300 μM. The polymer synthesis, for the polymersomes formation, 
was also done under inert conditions, but since the reaction is an anionic chain reaction, several 
factors can influence the length of the polymer (Fig.2.3.C). The polymersome formation was done 
by drying a thin layer of PEG17-PPS30 on a glass surface before adding 50 mM PBS solution and 
slowly rotating the solution for 3-4 days. The solution was extruded several times under high 
pressure through a 0.2 nm pore membrane until the size ranged between 140-170 nm (Fig.2.3.D).  
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Figure 2.3 Synthesis and formation of nanoparticles, polymersomes and their components. (A) F-127-COOH synthesis 
reaction. F-127-OH was reacted with maleic anhydride for 8 h under inert conditions in toluene before purifying the polymer by 
precipitation in ether. (B) Formation of nanoparticles and adjuvanted-nanoparticle conjugation. The first step of NP formation was an 
oil-in-water emulsions, where a 3:1 ratio of F-127-OH : F-127-COOH was dissolved in mQ H2O before adding propylene sulfide and 
polymerizing the core with the activated 4-Arm initiator. After blocking the free thiols with iodoacetamide, NPs were functionalized 
by reacting carboxyl groups with pyridyl disulfide cysteamine. Finally, a disulfide exchange reaction was performed to conjugate any 
thiol containing molecules. (C) PEG17-b-PPS30 block-copolymer synthesis. Under inert condition, benzyl mercaptan initiate an 
anionic chain reaction with propylene sulfide before stopping the reaction by adding PEG-OMs. (D) Polymersomes formation. The 
polymer, dissolved in DCM, was dried in piranha-etched vial before re-suspending it with 50 mM PBS and rotating it for 4 days. 
Afterwards, the solution was extruded and purified to remove free molecules. 
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Encapsulation of Poly(I:C) was not successful in either nanocarrier  
Poly(I:C) is a double-stranded RNA composed of a polyinosinic strand annealed with a 
polycytidylic strand. A high molecular weight (HMW) and a low molecular weight (LMW) can be 
purchased with a size range of 1.5-8 kb and 0.2-1 kb, respectively. We hypothesized that due to its 
properties (hydrophilic and the absence of thiols), the only possibility to deliver it, using our 
nanocarriers, was to encapsulate it in polymersomes. To determine the loading efficiency, the free 
adjuvant had to be removed from the solutions and the first method tested was a size exclusion 
chromatography with sepharose CL6-B beads (Fig.2.4.A, left). Unfortunately, the separation was 
not possible by size exclusion and so an anion exchange chromatography was performed. The free 
poly(I:C), negatively charged, was blocked in the column whereas polymersomes went through it 
without being disturbed by the charged column (Fig.2.4.A, middle). To confirm the removal of the 
free adjuvant from the solution, the anion exchange column was regenerated with 2 M NaOH or 
150 mM NaCl solvents, which released it (Fig. 2.4.A, right). Unfortunately, the quantification of 
the adjuvant by GelRed assay did not show any encapsulation and no further experiments were 
done with this adjuvant.  
 
 
 
Figure 2.4 Low molecular weight poly(I:C) encapsulation, and purification, in polymersomes. (A) Purification method of free 
poly(I:C) from encapsulated adjuvant. Left graph, separation between the two populations by size exclusion chromatography, with 
sepharose CL-6B beads, was not successful. Middle graph, the purification done by anionic exchange chromatography removed free 
adjuvant and the column could be regenerated with 2 M NaOH or 150 mM NaCl, right graph. (B) PS-Poly(I:C) encapsulation 
summary. The loading efficiency and particles sizes were obtained by GelRed assay and dynamic light scattering, respectively. The 
diffusion coefficient was calculated using Stokes-Einstein equation. 
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MPLA adsorption on nanoparticles and polymersomes 
The adsorption of the TLR-4 agonist on nanoparticles was done by dissolving it in DMSO, at 
a concentration of 7 mg/mL, and added dropwise to 400 μL of NPs. To increase the loading 
efficiency, the solution was strongly stirred during the addition. The following day, the mixture was 
purified by size exclusion chromatography using sepharose CL-6B beads (Fig.2.5.A, left). As a 
control, free MPLA was run through the column and since the presence of the free adjuvant was in 
later fractions than NPs, the purification was successful (Fig.2.5.A, middle). The quantification of 
MPLA was performed by HEK-blue TLR-4 assay and by fluorescently labeling the adjuvant. 
Unfortunately, the loading efficiency obtained by both methods varied significantly. The same 
sample showed 20% loading efficiency by fluorescence whereas 60% was obtained for HEK TLR-4 
assay. To determine if the adsorption influenced the interaction of MPLA with the TLR-4 receptor, 
BMDCs were incubated for 24 hours at different concentrations of free MPLA or NP-MPLA. The 
concentration of IL12p70, TNF? and IL6 cytokines showed similar trends between the two 
treatments with a small decrease when MPLA was adsorbed on nanoparticles (Fig.2.5.B). For the 
adsorption on the polymersome bilayer, the adjuvant was dissolved at the same time as the polymer 
in dichloromethane to form the thin layer on the HPLC glass vial. After extruding the 
polymersomes, the solution was purified by the same size exclusion chromatography as the 
nanoparticles solution (Fig.2.5.A, right). Polymersomes were detected between 3.5-4.5 mL, which 
correlates with the detection of MPLA whereas the free adjuvant exited after 7 mL. The 
quantification of the TLR-4 agonist was done again by fluorescence and HEK TLR-4 assay, which 
both gave a loading efficiency between 20-30%. The same activation experiment as the NP-MPLA 
was performed and, compared to free MPLA, a higher dose of PS-MPLA was needed to induce 
similar levels of IL12p70, TNF? and IL6. At 570 nM of MPLA, the levels of cytokines are identical 
independently of the presence, or not, of nanocarrier. The loading efficiency in polymersomes was 
always similar independently to the amount of starting material whereas the nanoparticle results 
varied strongly from batch to batch, and between quantification assays (Fig.2.5.D). Although 
MPLA could be adsorbed on both particles, the reproducibility of PS-MPLA compared to NP-
MPLA made it a more viable option for the following experiments. 
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Figure 2.5 MPLA, TLR-4 agonist, adsorption to nanocarriers and activation of BMDCs in vitro. (A) Size exclusion 
chromatography by sepharose CL-6B of NP-MPLA (left graph), Free MPLA (middle graph) and PS-MPLA (right graph). MPLA 
quantification was performed by HEK TLR-4 endotoxin assay, as well as by fluorescence, NP and PS detection was done with an 
iodine assay and HPLC in DMF, respectively. (B) BMDCs were incubated for 24h with different concentration of free MPLA or NP-
MPLA before collecting the supernatant and performing IL12p70, TNF? and IL6 ELISAs. (C) A similar experiment was performed 
as in (B) but this time with free MPLA or PS-MPLA, with identical readouts. (D) A summary of the adsorption efficiency with the 
different particles, their size obtained by DLS and diffusion coefficient calculated using the Stokes-Einstein equation. All 
Experiments were repeated three times in triplicate. 
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Polymersomes encapsulation of the TLR-7/8 agonist, CL075  
The delivery of CL075 was not possible with nanoparticles due to its chemical structure, 
which does not contain any thiols or any hydrophobic chains. Fortunately, the adjuvant is a small 
molecule, much smaller than poly(I:C) or even MPLA, making it possible to encapsulate it in 
polymersomes. The TLR-7/8 agonist was dissolved in a 50 mM PBS solution before adding it to the 
thin polymer layer and rotated for 4 days before extruding the solution. The separation of the 
encapsulated vs free adjuvant was done by a size exclusion chromatography, with sepharose CL-6B 
beads (Fig.2.6.A, left). The loading efficiency was calculated by quantifying the adjuvant 
concentration by HPLC with a gel permeation column in DMF (Fig.2.6.A, right). BMDC activation 
with free CL075, or encapsulated, induced similar concentration of IL12p70, TNF? and IL6 
(Fig.2.6.B). In addition, the highest dose tested had lower cytokine levels than a lower dose, which 
could indicate toxicity of the adjuvant for cells.  
 
 
 
Figure 2.6 CL075, TLR-7/8 agonist, purification and BMDC activation comparison between encapsulated vs free adjuvant. 
(A) Size exclusion chromatography with sepharose CL-6B beads (left graph) and adjuvanted-particles characteristics (right table). 
Quantification of CL075 and PSs were done by HPLC with a gpc column in DMF. BMDCs were incubated for 24h with different 
concentrations of free, or encapsulated, CL075 before collecting the supernatant and performing IL12p70, TNF? and IL6 ELISAs. 
All experiments were repeated three times. 
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CpG-B adjuvant, TLR-9 agonist, was chemically conjugated to nanoparticles  
CpG-B is a hydrophilic single stranded DNA, which does not naturally contain any thiols. To 
deliver it with nanoparticles, the adjuvant was purchased with a modification on the 5’end, where a 
thiol was added to the phosphate. Due to some difficulties conjugating the adjuvant to 
nanoparticles, different ratio of pyridyl disulfide cysteamine to CpG-B were tested to determine if 
the conjugation efficiency could be increased (Fig.2.7.A). The optimal ratio was when there was 
2.5x more PDC than CpG-B, whereas small changes in the ratio reduced the conjugation. 
Interestingly, the production of IL12p70 by BMDCs follows similar trends for low concentration of 
adjuvant whereas at higher doses, NP-CpG-B had higher levels of cytokines (Fig.2.7.B, left). TNF? 
production is also not influenced by the addition of nanoparticles (Fig.2.7.B, middle) whereas a 
decrease in IL10 was observed at all doses except the highest dose tested (Fig.2.7.B, right). Overall, 
the peak of cytokine production for the free adjuvant was at 0.41 μM and higher dose was toxic for 
the cells but the conjugated version induced higher concentration of cytokine at the 4.1 μM. Since 
CpG-B is hydrophilic, the encapsulation in polymersomes was tested, but the loading efficiency 
was below 1% and so was not further tested (Fig.2.7.C).  
 
 
Figure 2.7 CpG-B loading efficiency and BMDC activation, in vitro. (A) Size exclusion chromatography performed with 
sepharose CL-6B beads. From left to right, the ratio of PDC to CpG-B was 1.5, 2.5 and 3.5, respectively. (B) BMDCs were incubated 
for 24h with different concentration of free, or encapsulated, CpG-B before collecting the supernatant and performing IL12p70, 
TNF? and IL10 ELISAs. (C) size exclusion chromatography, similar as for NP-CpG-B, with PS-CpG-B. Adjuvant was quantified by 
GelRed assay and NPs by iodine assay. (D) Summary of the loading efficiency with the different particles, their size obtained by 
DLS and diffusion coefficient calculated using the Stokes-Einstein equation. All experiments were repeated three times. 
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The different diffusion coefficients were not influencing the cell uptake speed and 
both nanocarriers are endocytosed by macropinocytosis 
Since most of the in vitro experiments are done under static conditions and particles have 
different sizes, thus different diffusion coefficient, uptake experiments were performed to determine 
if there was an influence due to the size and the uptake route between particles. Fluorescently 
labeled OVA conjugated to NPs were incubated with BMDCs and the plate was either static or 
gently shaken. No difference in cell uptake was observed, since both conditions follow the same 
trends (Fig.2.8.A, left). Afterwards, the uptake of free OVA was compared to NP-OVA in static and 
shaken conditions, to determine if the differences in some cytokine concentration (Fig.2.5.C or 
Fig.2.6.B) were due to the delay in cell uptake caused by diffusion. Again, no significant difference 
for static and dynamic conditions was observed (Fig.2.8.A, middle & right). A similar experiment 
as in point A was performed but with free fluorescein (FITC) and PS-FITC. Again, no difference 
was observed in the cell uptake, when cells are incubated with PS-FITC under static conditions or 
dynamic mixing condition (Fig.2.8.B, left). The uptake of free or encapsulated FITC by BMDCs, 
under static or dynamic conditions, showed similar trends between the two treatments (Fig.2.8.B, 
middle & right). We were also interested in the uptake mechanism used by BMDCs for 
nanoparticles and polymersomes. A lower dose of amiloride, a macropinocytosis inhibitor, was 
needed to reduce the uptake of NPs than dynasore, a clathrin-mediated uptake inhibitor, and filipin 
III, a caveolae uptake inhibitor, but all three inhibitors were able to decrease to a certain extent 
uptake (Fig.2.8.C). Polymersomes also had a reduced uptake when cells were treated with amiloride 
and dynasore but not at all by filipin III (Fig.2.8.D). 
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Figure 2.8 Influence of the particle size on BMDCs uptake. (A) BMDCs were incubated with only NP-OVA-AF647 under static 
or dynamic conditions (left graph) and with free OVA-AF647, or conjugated, under either condition (middle & right graph). Left, 
BMDCs were incubated with NP-OVA-AF647 under static or shaken conditions before collecting the cells at different time point, 
washing them and quantifying their fluorescence. Middle & Right, BMDCs were incubated with free or NP conjugated OVA-AF647 
under static or dynamic condition, respectively, before collecting cells and quantifying fluorescence in cells. (B) BMDCs were 
incubated with only PS-FITC under static or dynamic conditions (left graph) and with free FITC or encapsulated, under either 
conditions (middle & right graph). Left, BMDCs were incubated with PS-FITC under static or shaken conditions before collecting 
the cells at different time point, washing them and quantifying their fluorescence. Middle & Right, BMDCs were incubated with free 
or PS conjugated FITC under static or dynamic condition, respectively, before collecting cells and quantifying fluorescence in cells. 
(C-D) BMDCs are treated with NP-OVA-AF647 or PS-OVA-AF647 for 4 h with three different cell uptake inhibitors, dynasore, 
filipin III and amiloride. All experiments were repeated twice. 
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2.5. Discussion 
 
The first goals of the study were to synthesis and understand the properties of the different 
nanocarriers, before attempting to formulate the different types of adjuvanted-particles. The first 
problem encountered with the synthesis of F-127-COOH was to remove the water molecules from 
the polymer. Initially, F-127-OH was dissolved in toluene and heated to reflux to remove the water 
using a Dean-Stark trap technique but, unfortunately, the temperature needed was too high and 
caused the polymer to crash out of the solution. Thankfully, this issue was solved by dissolving the 
polymer in dichloromethane before precipitating it in methanol and drying it overnight. The 
formation of the nanoparticle and its size was reproducible but the functionalization would vary 
between reactions. To determine if it was possible to decrease the variation between batches, the 
reaction was repeated a second time and only a 2x increase was observed, which was not enough 
for it to be incorporated in the protocol. Indeed, the only molecule influenced by the concentration 
of PDC was CpG-B and the value obtained with the 2nd reaction was still too low to induce a good 
conjugation. In the case of the PEG17-b-PPS30 polymer used for the formation of polymersomes, it 
was an obligation to have a number of propylene sulfide monomeric units between 28-30 since the 
vesicles would not form with higher values. The most important factors controlling the chain length 
were the purity of PEG-OMs and the accidental incorporation of oxygen when transferring the 
mesylated-PEG in the reaction flask. Overall, if the molecule of interest was hydrophobic, three 
options were possible to deliver it with either vehicle. It could be encapsulated in the nanoparticle 
core during its formation or adsorbed on its surface once NPs were already formed. The surface 
adsorption was possible only if the molecule contained one, or several, hydrophobic tails. For 
polymersomes, it could either be dissolved with the polymer before the formation of a thin layer or 
once particles were already form. A hydrophilic molecule containing a thiol could be conjugated to 
nanoparticle thanks to a disulfide exchange reaction with the PDC groups and finally, any 
hydrophilic molecule, if not too big, could be encapsulated in polymersomes. 
 
Unfortunately, the TLR-3 agonist tested could not be encapsulated in polymersomes, due to 
its size and so another vehicle should be developed in order to be able to deliver it. Currently, in 
vaccines using Poly(I:C) as adjuvant, Poly(I:C) is complexed to a positively charged particle such 
as chitosan polymer, PLGA or polyethylenimine (PEI) 94, 95, 96. All articles mentioned previously 
took advantage of the negatively charged adjuvant to deliver it by electrostatic interaction. Velutto 
et al 97 synthesized and used a PEG44-PPS40-PEI120 polymer to deliver plasmid OVA in B16-F10 
melanoma and increased the immune response against the tumor. A solution for this adjuvant would 
be to either use the same construct mentioned previously or add PEI to the polymer used for our 
polymersomes.  
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Inversely to poly(I:C), the second adjuvant, MPLA, could be adsorbed on both nanocarriers 
thanks to its hydrophobic property. Since the quantification by HEK-blue TLR-4 assay determines 
the effective concentration of MPLA, which could underestimate the correct concentration, MPLA 
was also fluorescently labeled and quantified. Values obtained for PSs, were exactly the same 
independently of the assay, whereas the concentration of adjuvant when adsorbed on nanoparticles 
varied between 20-60% between assays. In addition, the result of HEK-blue TLR-4 endotoxin assay 
had several false positives, indicating an overestimation of the concentration and a possibility of 
aggregation of nanoparticles. A dose of MPLA higher than 570 nM, for BMDCs activation, induced 
lower cytokine levels compared to a lower dose, indicating either toxicity or exhaustion of cells due 
to an over activation. Although the same dose of MPLA, either free or adsorbed on PSs, was added 
to BMDCs, lower levels of cytokines were detected for the PS-MPLA conditions. An explanation 
would be that several adjuvants are adsorbed on one particle and thus the overall number of cells 
activated would be lower. 
 
The TLR-7/8 agonist was adsorbed in polymersomes, as was MPLA, and purified by size 
exclusion chromatography. The activation of BMDCs with different concentrations of adjuvant 
showed exactly the same levels of cytokines independently of the presence of nanocarrier and, 
again, the higher dose induced exhaustion or cell death. The adjuvant could also be incorporated in 
the nanoparticle hydrophobic core but, due to technical reasons, it was not tested. Indeed, the 
quantification of CL075 was done by HPLC in an organic GPC column after lyophilizing a sample 
and resuspending it in an organic solvent. This approach would not release the adjuvant from the 
nanoparticle due to the cross-linking of the core and so another solution should be found to quantify 
it. 
 
Different ratios of pyridyl disulfide cysteamine to CpG-B were tested to determine the best 
conjugation efficiency. The optimal ratio found was 2.5 and the conjugation decreased drastically if 
the ratio changes of ±1. Concerning the activation of BMDCs, in vitro, IL12p70 concentration 
followed the same trends as the free adjuvant but, at high doses, higher cytokine levels were present 
when CpG-B was conjugated. An explanation for this result would be a reduced toxicity of the 
adjuvant when delivered by nanoparticles since the highest dose tested, 1 μM, had similar, or lower, 
cytokine levels when treated with free CpG-B. A slight decrease in IL10 cytokine was also 
observed when cells were treated with NP-CpG-B, which would be an advantage for the vaccine 
since this cytokine is known to downregulate the expression of TH1 cytokines, MHC-II antigens and 
co-stimulatory molecules. The encapsulation in polymersomes was not successful because there 
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was no interaction driving the ssDNA to enter the vesicle. The same polymer structure discussed for 
the poly(I:C) adjuvant could be used for CpG-B since it is also negatively charged.  
 
Finally, to verify that the difference observed in BMDC activation experiments was not due 
to the different sizes and diffusion coefficients, uptake experiments were performed. Indeed, since 
all the in vitro experiments are done under static condition, it was important to verify if the uptake 
speed varied between free OVA or particulated OVA. First of all, cells were taking up NP-OVA at 
the same speed independently of the conditions, static or shaken. The small difference observed 
under static conditions between NP-OVA and free OVA protein could be explained by the fact that 
one nanoparticle had several proteins conjugated to it and so, as soon as the cell endocytoses a 
particle, the concentration of OVA will increase more rapidly than in the case of the free OVA 
conditions. This effect was also observed under dynamic conditions, but both conditions follow 
exactly the same trends. Similar results as for NP-OVA were observed when cells were incubated 
with free FITC or encapsulated, PS-FITC. The uptake of nanoparticles by BMDCs was inhibited 
when cells were incubated with dynasore or amiloride but not as strongly with filipin III, indicating 
a preferential macropinocytosis and clathring-mediated uptake rather than a caveolae mechanism. 
Polymersomes were also engulfed by BMDCs through the same mechanism but they were not 
influenced by Filipin III inhibitor indicating no uptake by caveolae-mediated pathway. Indeed, the 
vesicle size formed by caveolae-mediated ranges around 60 nm making it impossible for PSs, 140-
170 nm, to use this pathway to enter the cells. 
 
Overall, three different adjuvants could be successfully encapsulated, conjugated or adsorbed 
on either nanocarriers without strongly affecting their activations on BMDCs. In addition, the 
different diffusion coefficient did not influence their uptake by BMDCs. The next study was to test 
the different adjuvanted-particles in combination to determine if synergistic activation could be 
observed. 
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Chapter 3 
3.  
Combinatorial in vitro and in vivo screening of adjuvanted-
nanoparticulates 
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3.1. Abstract 
 
One essential aspect in the development of an efficient therapeutic cancer vaccine is the 
delivery of immunostimulatory molecules that rationally target appropriate molecular pathways 
with the purpose of optimally inducing strong T cell immune responses. Their dose, 
physicochemical properties, toxicity, and the delivery system can all directly impact the magnitude 
and characteristics of the resulting immune response. One of the most common adjuvants used in 
vaccines nowadays are Toll-like receptor agonists but the toxicity associated with the dose needed 
to induce a strong immune response is still an issue. Several studies showed synergistic effects 
when co-targeting multiple TLRs, leading to a decrease in the required dose for a meaningful 
response, but such approaches also required the adjuvants to be co-delivered on the same delivery 
platform. In this section, we asked if combinatorial delivery of multiple nanoparticles, each 
harboring a different adjuvant, can produce similar synergistic effects in terms of BMDC activation 
in vitro, and further, if such in vitro screens may translate to optimal T cell immune responses in 
vitro or in vivo.  
 
The combination of PS-CL075 with NP-CpG-B induced the least synergistic effect in 
cytokine secretion after activating BMDCs, in vitro. On the other hand, strong effects were obtained 
when combining PS-MPLA with either PS-CL075 or NP-CpG-B. In addition, the secretion of IL10 
was induced by DCs due to the too strong activation occurring with certain adjuvant combinations. 
However, the formulations that performed the best in the in vitro BMDC screen did not translate to 
enhance T cell immune responses, in vitro and in vivo. Finally, the most promising adjuvant 
combination obtained was when a 1:5 ratio of NP-CpG-B with PS-MPLA were co-injected since a 
clear decrease in tumor growth was observed and it is worth noting that this combination did not 
increase T cell immune response. First of all, these results suggest that although synergistic effects 
were observed when activating two different TLR pathways, BMDCs activation in vitro did not 
allow to fully understand its activation potential since IL10 secretion was induced for certain 
adjuvant combinations, which can be due to the experimental limitations. In addition, the 
mechanism by which adjuvant-mediated lymphocyte immune response is not a straightforward 
process, and several other parameters, as well as the environment, come into account for their 
activation. 
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3.2. Introduction 
 
One of the reasons for the safety of subunit vaccines is because they are not composed of the 
entire pathogen but only the most dominant antigens, thereby focusing the education of the adaptive 
immune response to the components of the pathogen 98. In addition, live-attenuated or inactivated 
viruses used in vaccines have a broad range of immunostimulatory molecules, creating a good 
combination of signals to induce a strong and protective immune response against the disease 99. 
Usually, adjuvants are incorporated into vaccines to increase their efficacy, but in spite of this, the 
most effective form of it is still not comparable to vaccination with entire pathogens. Because this is 
obviously a non-ideal solution due to biosafety concerns, building effective and safe vaccines 
requires improving the immunogenicity of subunit vaccine formulations. The simplest way of 
accomplishing this was to increase the amount of adjuvants used, but this approach also increases 
the risk of side effects, which can range from a simple rash to the development of autoimmune 
disease or worse 100 . This illustrates that the optimization of subunit vaccine efficacy and 
immunogenicity requires a fine equilibrium between toxicity and strength of the immune activation.  
 
An alternative approach to this problem would be to increase the organ or cellular targeting 
efficiency, either by direct injection of vaccine formulations in the correct anatomic location or 
using methods to increase retention time in the targeted organ. Such an approach would decrease 
the risk of side effects, awhile potentially decreasing the amount of adjuvants needed to induce the 
same response as a higher dose administered systemically 101. Following the same logic, others have 
achieved the same ends through adjuvant delivery with nanocarriers specifically designed to target 
specific anatomic locations 102, 103, or adding targeting molecules to the vaccine to interact only with 
the cell/organ of interest 104, 105. Our laboratory has used such approaches by delivering CpG-B with 
NPs to induce a similar response at a lower dose than the free TLR-9 agonist due to a higher 
drainage efficacy to the lymph node and an increased uptake by APCs 48. 
 
Another strategy to improve adaptive immune responses at lower doses of adjuvant would be 
to combine adjuvants targeted to multiple immune activation pathways, with the goals of inducing 
synergistic effects 105. The most common and well-studied adjuvants are a subset of the pattern 
recognition receptors family, called Toll-like receptors. The stimulation of TLRs induce a 
conformational change, which in turn initiate a cascade of events resulting in the production of 
cytokines, chemokines and co-stimulatory molecules, depending on the type of agonist used 
(Fig.3.1).  
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106 
The rationale in targeting different immune activation pathways is the potential to induce a 
broader range of cytokines secreted by the cell, thereby increasing the diversity and magnitude of 
the resulting immune response. Kasturi et al. showed an increase in antigen-specific neutralizing 
antibodies when the antigen, a TLR-9 and a TLR-7/8 agonist were co-delivered in PLGA 
nanoparticles, versus when single TLR agonists were co-administered with the antigen 107. Another 
group showed a synergistic effect when the TLR-4 and TLR-7/8 agonists were co-delivered within 
a liposome, magnifying the activation of the adaptive immune response 108, 109. Finally, co-targeting 
the TLR-4 and TLR-9 has also been shown to improve the inflammatory activation of macrophages 
109. In all of these cases, the adjuvant combinations were co-delivered on the same delivery system, 
with the potential of activating different pathways within the same cell. The adjuvant 
concentrations, within these studies, are never varied and so an open question remains as if there 
was an optimal adjuvant ratio combination to further increase even more the synergistic effect. 
 
For this purpose, we performed a combinatorial screening of our adjuvanted-particles in vitro 
to determine synergistic effects, even though the adjuvants are no longer on the same delivery 
system and to determine if the adjuvant ratio influences the immune response. Finally, we 
determined if the synergistic effects translated in an increased T cell immune response in vitro and 
in vivo 
  
Figure 3.1 Pattern recognition receptors activating innate immune response and 
their subcellular location. Image adapted from Reed et al 106 
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3.3. Materials and Methods 
Animals 
All mice used in experiments were C57BL/6 female 8-12 weeks old, purchased from Harlan 
(France) or Jackson Laboratory (Bar Harbor, Maine, USA). OT-I and OT-II mice, C57BL/6-
Tg(TcraTcrb)1100Mjb/J and B6.Cg-Tg(TcraTcrb)425Cbn/J, respectively, were purchased from 
Jackson Laboratory. All procedures were performed in compliance with the Veterinary Authority of 
the Canton of Vaud (Switzerland) according to Swiss laws and the Institutional Animal Care and 
Use Committee at the University of Chicago (USA). 
Cell line 
The melanoma B16-F10 expressing ovalbumin (B16-OVA) cells line was gifted from 
Bertrand Huard (University of Geneva, Switzerland) and was maintained in high glucose DMEM 
(Gibco, Waltham, Massachusetts, USA; Catalog # 11995) supplemented with 10% FBS. 
Materials, Reagents, and Antibodies 
Reagent grade chemicals were purchased from Sigma-Aldrich (Saint Louis, MO, USA) unless 
noted otherwise. All adjuvants, except for CpG-B, were purchased from InvivoGen (San Diego, 
CA, USA). The modified 5’SPO3-CpG-B (5’-TCCATGACGTTCCTGACGTT-3’) was purchased 
from Microsynth (Balgach, Switzerland) or TriLink Biotechnologies (San Diego, CA, USA). All 
materials for cell culture were purchased from Invitrogen/Gibco (Waltham, Massachusetts, USA) 
unless otherwise noted. 
Anti-mouse antibodies CD11c (clone N418), MHC-II (clone M5/114.15.2) were purchased 
from BioLegend (San Diego, CA, USA) whereas live/dead fixable, CD80 (clone 16-10A1), CD86 
(clone GL1), CD40 (clone 3/23), CD8 (clone 53-6.7), CD4 (clone RM4-5), IFN? (XMG1.2), CD25 
(clone PC61), IL2 (clone JES6-5H4), CD45 (clone 30-F11), CD3 (clone 145-2C11), FoxP3 (clone 
MF23), TNF? (MP6-XT22), CD62L (clone MEL-14) and CD44 (clone IM7) were from 
ThermoFisher Scientific (Waltham, MA, USA). The SIINFEKL-specific pentamer, PE-labeled H-
2Kb/OVA257-264 was purchased from Proimmune (Oxford, UK). 
Generation of Bone marrow-derived dendritic cells (BMDCs) 
An adapted version of the protocol described by Lutz et al 93 was used to generate CD11c+ 
BMDCs. Briefly, bone marrow cells were isolated from a C57BL/6 mouse and cultured for 9 days 
with 20 ng/mL of GM-CSF. The media was replaced with fresh media every 3 days until day 6 after 
isolation. At day 9, because 70-85% of the non-adherent cell population expresses the signature 
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dendritic cell marker CD11c+, the bulk unsorted non-adherent cells were used in downstream 
studies detailed below.  
BMDC activation experiments 
All BMDC activation experiments were performed in a tissue culture-treated U-bottom 96-
well polystyrene plates. They were done with 200’000 cells per well and incubated at 37°C in a 5% 
CO2 incubator. Cytokine quantification in the cell culture supernatant was performed following 24 
h of incubation, whereas cell phenotype analysis by flow cytometry was performed after 6 h. 
BMDC-CD4+ or CD8+ T cell co-culture experiments 
To link BMDC phenotype to T cell activation, BMDCs were co-cultured with CD4+ or CD8+ 
T cells. BMDCs were pre-activated overnight with combinatorial adjuvant formulations and 5 μM 
ovalbumin (OVA), after which the supernatant was collected (stored at -20°C) for further analysis 
via ELISAs. The BMDCs were washed once with PBS. OVA-specific CD4+ or CD8+ T cells were 
isolated from the spleen of OT-II or OT-I transgenic mice, respectively, and purified using the 
EasySepTM Mouse T cell isolation kit (Stemcell Technologies, Vancouver, CA) following the 
manufacturer’s protocol. T cells were then fluorescently labeled with CFSE (eBioscience, Waltham, 
MA, USA), and added to the BMDCs at a 1:10 DC:T ratio. Co-culture media (Iscove’s Modified 
Dulbecco’s Medium; IMDM, supplemented with 10% FBS, 102 U/mL penicillin and 102 ?g/mL 
streptomycin) was supplemented with OVA for the entirety of the experiment. Co-cultures were 
incubated for 3 days, after which cell secretion of cytokine was halted through the addition of 
brefeldin A (final concentration of 5 μg/mL), enabling facile detection of cytokine production at a 
single-cell level through flow cytometry. After 3h, cells were stained for flow cytometry analysis. 
Tumor inoculation and immunizations 
An orthotopic injectable melanoma model was employed through the intradermal (i.d.) 
injection of B16-OVA tumor cells. To expose the injection site, healthy adult wild-type C57BL/6 
mice were anesthetized with isoflurane (3.5%), and the dorsal scapular skin on the mouse’s right 
side was shaved and disinfected. 2.5 x 105 B16-OVA tumor cells in 30-45 μL of 0.9% saline 
solution were delivered intradermally at this site. All nanoparticle adjuvants were prepared as 
explained in the previous chapter, and conformed for low endotoxins levels by HEK-blueTM TLR-4 
assay. The formulations were mixed right before the vaccination, which was administered i.d. in the 
forelimb, draining the same lymph node as the tumor. The maximum volume injected was 30 μL. 
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Starting on day 4 post-inoculation, tumors were measured every other day with digital 
calipers and the volume was calculated using an ellipsoidal equation: ? ? ????
?
??
?
? ?
?
? , where L 
is the length, W is the width and H is the height. 
 
Whole organ/tumor processing into single-cell suspensions 
To analyze immune responses within specific anatomic compartments, the tumor-draining 
lymph node (TdLN), the spleen and the tumor were harvested and processed into single-cell 
suspensions for flow cytometry. For the TdLN and the spleen, cell suspensions were obtained by 
mechanically disrupting the organ and rinsing with PBS, or IMDM, through a 0.7 μm cell strainer 
(CorningTM, NY, USA), and then centrifuging the resulting cell suspension at 1500 rpm for 5 min. 
The TdLN was then resuspended in IMDM supplemented with 10% FBS, 102 U/mL penicillin, 102 
?g/mL streptomycin and 20 μM 2-mercaptoethanol (Full media) and counted. Splenocytes were 
first washed in a hypotonic solution of ammonium chloride-potassium bicarbonate (ACK) for 2 min 
to remove red blood cells, prior to centrifugation at 1500 rpm for 5 min, resuspension in full media 
and counting. The tumor cell suspension was obtained by adapting a protocol from Broggi et al 110. 
Briefly, the tumor was minced, and then digested in digestion media (DMEM + 2% FBS + 1.2 mM 
CaCl2 + 102 U/mL penicillin + 102 ?g/mL streptomycin) supplemented with 1 mg/mL Collagenase 
IV and 40 μg/mL DNAse I (Worthington Biochemical Corp, Lakewood, New Jersey, USA). This 
suspension was gently stirred at 37°C for 30 min, further disrupted by repetitively pipetting 100x, 
and then filtered through a 70 μm strainer. The remaining undigested tumor fragments were further 
digested at 37°C for 1 h in a second digestion mix consisting of digestion buffer supplemented with 
3.5 mg/mL Collagenase D and 40 μg/mL DNAse I. The tumor fragments were further mechanically 
disrupted through repetitive pipetting them 100x. The enzymes were quenched through the addition 
of EDTA to a final concentration of 2.5 mM, and then the cell suspensions were filtered through a 
70 μm strainer and combined with the cells from the first digestion step. As tumors may contain a 
significant amount of blood, the resulting cell suspensions were treated similarly to the splenocytes 
described above before they were resuspended in full media and counted.  
Ex vivo restimulation 
For the reactivation of antigen-specific T cells in TdLNs and spleens, these organs were 
processed into single-cell suspensions as described above, and then plated in U-bottom 96-well 
plates at up to 2 ? 106 cells/well. The cells were incubated at 37°C in a 5% CO2 incubator with 2 
μg/mL of antigenic peptide in full medium. For cytokine quantification by ELISA, supernatants 
were collected following 4 days of incubation, whereas for flow cytometry analysis, cells were 
incubated for 3 h prior to halting cytokine export through the addition of brefeldin A to a final 
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concentration of 5 μg/mL, followed by incubation for an additional 3 h before harvest.  To re-
stimulate antigen-specific CD8+ T cells, the MHC-I-dominant peptides OVA257-264 (SIINFEKL), 
TRP-2181-188 or gp10025-33 were used, whereas CD4+ T cells were reactivated with OVA323-339. 
Flow cytometry 
Cell suspensions were centrifuged and washed with 1x PBS, and then incubated with a fixable 
live/dead at 4°C for 15 min (eBioscience) and washed once with PBS. Antigen-specific T cells were 
detected via pentamer staining, which was performed by incubating cells at room temperature in a 
solution of 1x PBS supplemented with 2% FBS (staining buffer), for 20-30 min. For surface 
staining, a cocktail of antibody was diluted in staining buffer and incubated at 4°C for 15 min in the 
dark. Intracellular staining and intranuclear staining were performed with the BD 
cytofix/cytopermTM Kit or FoxP3 staining kit, respectively, according to the manufacturer’s 
instructions. Finally, the cells were washed with staining buffer and stored in the same buffer for 
data collection. 
ELISA 
Cytokines detection and quantification were performed with Ready-SET-Go! ELISA kits 
purchased from ThermoFisher Scientific and used according to the manufacturer’s instructions. 
Data collection 
Flow cytometry was performed using either a CyAnTM ADP (Beckman Coulter, Brea, CA 
USA) or a BD LSRFortessaTM (BD Biosciences, San Jose, CA, USA). The data obtained were 
analyzed with FlowJo (v.10, FlowJo LLC, Ashland, OR, USA). Graphs and statistical analysis were 
done using the GraphPad Prism 7 Software (GraphPad Software Inc, La Jolla, CA, USA). 
Synergistic effect was defined as an effect higher than the sum of the individual adjuvant and noted 
with a *. Statistical significance between the different groups in vivo was determined with a one-
way analysis of variance (ANOVA) followed by a Bonferroni post-test correction. * and ** indicate 
P values less than 0.05 and 0.01, respectively. 
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3.4. Results 
Based on our results in the previous chapter showing the efficacy of nanoparticle adjuvants to 
activate BMDCs in vitro, the next question was if combinatorial administration of multiple 
adjuvanted-nanoparticles might lead to synergistic effects in BMDC activation, and subsequently, T 
cell-mediated immune responses, in vitro and in vivo. Specifically, nanoparticle adjuvants targeting 
any pair of different TLR pathways were co-administered in order to characterize dose responses in 
an in vitro screen, followed by administration of the most efficacious combinations, in vivo, in an 
orthotopic aggressive melanoma model.  
 
Combining PS-MPLA with PS-CL075 promotes synergistic effects on BMDC 
activation and cytokine production by CD4+ T cells in vitro 
To investigate combinatorial activation of TLR-4 and TLR-7/8, PS-MPLA and PS-CL075 
were co-administered, and BMDC activation was quantified based on their cytokine production and 
surface expression of co-stimulatory molecules. For both adjuvants, dosing was based on the dose 
response experiments performed in the previous chapter (Fig.2.5.B & Fig.2.6.B). BMDCs were 
incubated for 24 h or 6 h, before collecting the supernatant, for cytokines quantification by ELISA, 
and cells, for co-stimulatory detection by flow cytometry analysis, respectively (Fig.3.2.A-B). At a 
fixed dose of PS-MPLA, the addition of 0.4 μM of PS-CL075 was sufficient to synergize in the 
production of TNF?, by 2-fold, and IL12p70, between 2- to 4-fold, depending on the PS-MPLA 
dose (Fig.3.2.A, left & middle). The secretion of IL10 was also increased at high doses of PS-
CL075 (Fig.3.2.A, right). The activation of BMDCs showed no synergistic effect between 
combinations, except for an upregulation in the expression of CD40 for all treatments (Fig.3.2.B). 
Overall all proinflammatory cytokines tested were increased and 4 μM PS-CL075 did not further 
increase it compared to the medium dose.  
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Figure 3.2 BMDCs activation with different PS-MPLA and PS-CL075 combinations showed synergistic effect for 
proinflammatory cytokines and CD40 expression. (A) Cytokine concentration. Cells were incubated with different doses of PS-
MPLA and PS-CL075, for 24 h, before collecting the supernatant and quantifying the cytokines via ELISA. (B) BMDCs activation 
markers quantification by flow cytometry. Results are representative of two independent repeats, and * represent synergistic effects 
observed for that specific combination. 
To test if the most efficacious combinations at triggering BMDC activation would also 
consequently induce optimal activation of CD8+ or CD4+ T cells, adjuvant-activated BMDCs were 
co-cultured with OVA-reactive OT-I or OT-II cells (Figure 3.3).   
 
The three combinations used for co-cultures were the ones inducing the strongest synergistic 
effect with different adjuvant formulation ratio, 1:7 and 1:80 of PS-MPLA:PS-CL075. Generally, 
PS-MPLA and PS-CL075 did not synergize to promote enhanced CD8+ T cell activation, although a 
significant improvement in IL-2 secretion and a small but non-significant increase in proliferation 
was seen following co-administration at a 1:7 PS-MPLA:PS-CL075 (Fig.3.3.A-B). Focusing on the 
canonical CD8+ T cell effector cytokines, Granzyme B was not increased with the different 
conditions, and IFN? was even decreased when a high dose of PS-CL075 was mixed with PS-
MPLA, at any dose (Fig.3.3.A). On the other hand, combining PS-MPLA and PS-CL075 
contributed to additive effect on IFN? secretion in CD4+ T cells at low doses (Fig.3.3.C, left), but 
not IL2 production since it followed the same curve as the PS-MPLA single adjuvant (Fig.3.3.C, 
right). The flow cytometry analysis showed no difference in proliferation between all conditions 
(Fig.3.3.D, left), but an increase in IL2+ and IFN?+ single positive CD4+ TEff/EM cells, when a high 
dose of PS-CL075, combined with a medium dose of PS-MPLA, was observed (Fig.3.3.D, middle 
& right). 
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Figure 3.3 An increase in cytokine positive CD4+ TEff/EM but not CD8+ TEff/EM cells was observed. 15’000 BMDCs were 
activated overnight with OVA and different adjuvant combinations before removing the adjuvant formulation and adding CFSE 
labeled OT-I or OT-II. After three days, the supernatant was collected for cytokine quantification, by ELISA, and cells were staining 
for flow cytometry analysis. (A) Granzyme B, IFN? and IL2 cytokines concentrations in the supernatant. (B) Flow cytometry of 
CD8+ T cells proliferation, activation marker and cytokine production. (C) IFN? and IL2 concentrations in the supernatant. (D) Flow 
cytometry of CD4+ T cells proliferation and activation markers. Results are representative of three independent repeats, and * 
represent synergistic effects observed for that specific adjuvant combination. 
 
44 
 
The addition of PS-CL075 to PS-MPLA slightly increased the percentage of 
polyfunctional CD4+ & CD8+ T cells but did not reduce tumor growth 
 
While the PS-MPLA/PS-CL075 combination synergized in BMDC activation, it only 
translated into an additive effect for T cell activation in vitro. On the other hand, in an in vivo 
setting, the limitation observed in vitro are less likely to occur and in addition, a multitude of other 
cells influence the activation of T cell-mediated immune response, which were not taken into 
account in vitro. Therefore, two different adjuvant formulations were tested in a therapeutic vaccine 
setting, wherein tumor-bearing mice were treated with a vaccine draining the same LN. The 
different factors considered when preparing the in vivo experiment were the vaccination strategy, 
the model used and the doses tested. Our lab had shown previously that although the TdLN was 
considered immunosuppressive, it was possible to reprogram it and still induce a cytotoxic CD8+ T 
cells response 63. Based on this study, B16-OVA cells were inoculated on the right dorsal scapular 
skin, and vaccinated, 7 days post tumor cell inoculation. The vaccine was administered i.d. in the 
forelimb draining the TdLN (Fig.3.4.A). 5 μg/mouse of PS-MPLA was used and two different 
doses of PS-CL075 were tested, 5 and 15 μg/mouse, which was already higher for the TLR-7/8 than 
what has been published with this adjuvant 111. PS-MPLA alone slightly slowed the tumor growth 
compared to the mock injection (Fig.3.4.B), and it correlated with an increase in the frequency of 
SIINFEKL-specific CD8+ T cells in both the tumor (49 ± 6.6 fold increase) and the spleen 
(Fig.3.4.C). On the other hand, PS-CL075 alone did not affect tumor growth despite a small 
increase in tumor antigen-specific CD8+ T cells in the tumor and spleen. When PS-MPLA and PS-
CL075 were combined, no synergistic effects in terms of decrease tumor growth or increases in 
tumor antigen-specific CD8+ T cells was detected (Fig.3.4.B-C) but similar results to PS-MPLA 
alone were observed. 
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Figure 3.4 The addition of PS-CL075 to PS-MPLA did not delay tumor growth or increase antigen specific CD8+ T cells. 2.5 x 
105 B16-OVA cells were inoculated i.d. in the right dorsal scapular skin. Mice were vaccinated, i.d. in the forelimb draining to the 
same lymph node as the tumor, 7 days post tumor inoculation, before sacrificing the mice on day 14. (A) Experimental timeline, 
groups and dose. (B) Overall, and individual, tumor growth. (C) Percentage of SIINFEKL-specific CD8+ T cells in the tumor 
microenvironment and the spleen quantified by SIINFEKL-MHC-I pentamer staining. Error bars indicate SEM for (B) and SD for 
(C) the other. N = 3 mice per groups. *P < 0.05. 
 
To assess if the vaccination induced a T cell immune response, the spleen and the tumor-
draining lymph node were restimulated with the MHC-I or MHC-II dominant tumor antigens 
(SIINFEKL and OVA327-339). Following the experimental timeline shown previously (Fig.3.3.A), 
PS-MPLA alone increased the production of granzyme B and IFN? relative to mock injected mice. 
These cytokines were all decreased when PS-CL075 was co-injected with PS-MPLA, 
independently of the dose (Fig.3.5.A). Inversely, a small increase in polyfunctional CD8+ T cells 
were observed in the spleen for all vaccinated groups (Fig.3.5.B, left) and only the high dose of PS-
CL075 with PS-MPLA induced a higher proportion of polyfunctional CD4+ T cells compared to the 
other groups (Fig.3.5.B, right). In the tumor-draining lymph node, the granzyme B production was 
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similar to the one in the spleen between the different groups (Fig.3.5.C, left) whereas IFN? was 
significantly increased in all treatments compared to mock injected mice (Fig.3.5.C, right). Finally, 
the proportion of polyfunctional CD8+ or CD4+ T cells were not significantly increased compared to 
the negative control group, but a trend for the combined adjuvants was observed in CD8+ T cells 
(Fig.3.5.D). 
 
 
Figure 3.5 A decrease in granzyme B and IFN? secretion were observed for co-administered adjuvant compared to PS-
MPLA only. 2.5 x 105 B16-OVA cells were inoculated i.d. in the right scapular dorsal skin. Mice were vaccinated, i.d. in the 
forelimb draining to the TdLN, 7 days post tumor inoculation before sacrificed on day 14. (A & C) Granzyme B and IFN? 
concentration in the supernatant after SIINFEKL reactivation in the spleen and TdLN, respectively. (B & D) Polyfunctional T cells 
in the spleen and TdLN, respectively. Polyfunctional cells were T cell secreting two or three of the cytokine: IL2, IFN? or TNF?. 
Error bars are SD and N = 3 mice per groups. *P < 0.05. 
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Combining PS-CL075 with NP-CpG-B induced synergistic effects for TNF? 
secretion in BMDCs activation as well as CD4+ T cell cytokine expression, in vitro 
 
Synergy between targeting of TLR-7/8 and TLR-9 via the nanoparticle adjuvants PS-CL075 
and NP-CpG-B, respectively, was evaluated in assays for DC activation and T cell activation in 
similar fashion as for the previous adjuvant combination (Fig.3.6.A). First of all, the optimal dose 
of NP-CpG-B for the secretion of cytokines was 0.1 μM independently of the presence of PS-
CL075. Secondly, a synergistic effect was observed for the secretion of TNF? already when a small 
dose of the TLR-7/8 agonist was added to 0.1 μM NP-CpG-B but an increase in PS-CL075 
concentration did not correlate with higher synergistic effect (Fig.3.6.A, left). The highest dose of 
NP-CpG-B, alone or combined, induced lower concentration of all three cytokines quantified. The 
flow cytometry analysis showed additive effect in percentage of MHC-IIhi DCs as well as CD80+ 
CD86+ co-expression and CD40 when 0.01 μM NP-CpG-B was combined to PS-CL075 at any 
concentration (Fig.3.6.B, left). The addition of the TLR-7/8 agonist to the two other doses of NP-
CpG-B did not increase the DC activation or co-stimulatory molecules  
 
 
 
Figure 3.6 Only TNF? production was synergistically increased when 0.1 μM NP-CpG-B was incubated with PS-CL075. (A) 
Cytokines concentration in supernatant after 24 h activation quantified by ELISA (B) BMDCs activation markers quantification by 
flow cytometry. Results are representative of two independent repeats and * represent synergistic effects observed for that specific 
dose 
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Based on the results obtained for the BMDC activation experiment, the most promising 
treatments were tested for their efficacy to indirectly induce CD4+ or CD8+ T cells activation 
through DCs with co-culture experiments. The combination tested were all three doses of PS-
CL075 with 0.1μM NP-CpG-B. The three different cytokines quantified showed very different 
trends within the same treatment for CD8+ T cell co-culture (Fig.3.7.A). For example, the same 
combination of PS-CL075 and NP-CpG-B induced a lowered concentration of granzyme B, had no 
effect on the production of IFN? compared to NP-CpG-B only, but increased significantly the 
secretion of IL2. CD8+ T cell analysis showed no synergistic effect in proliferation index 
(Fig.3.7.B, left) or the percentage of CD25+ CD8+ T cells (Fig.3.7.B, right), but a small increase in 
IFN?+ CD8+ T cells (Fig.3.7.B, middle), when both adjuvants were combined. The CD4+ T cell co-
culture showed a slight decrease in IFN? secretion but no variation in the IL2 for the combination of 
both adjuvants (Fig.3.7.C). The CD4+ T cell analysis showed no differences in the proliferation 
index, the proportion of IFN? cells and the fluorescence of IL2 between the different combinations 
(Fig.3.7.D). 
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Figure 3.7 Synergistic effect for IL2 secretion in CD8+ T cells activation and a small increase in IFN?+ CD4+ T cells was 
detected when combining adjuvants. 15’000 BMDCs were activated overnight with OVA and different adjuvant combinations 
before removing the adjuvant formulation and adding CFSE labeled OT-I or OT-II. After three days, the supernatant was collected 
for cytokine quantification, by ELISA, and cells were staining for flow cytometry analysis. (A) Granzyme B, IFN? and IL2 cytokines 
concentrations.in the supernatant. (B) Flow cytometry of CD8+ T cells proliferation, activation marker and cytokine production. (C) 
IFN? and IL2 cytokines concentrations in the supernatant. (D) Flow cytometry of CD4+ T cells proliferation and activation markers. 
Results are representative of three independent repeats, and * represent synergistic effects observed for that specific adjuvant 
combination. 
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At the dose tested, no enhance in the immune response was observed for the 
combination of PS-CL075 with NP-CpG-B, in tumor bearing mice 
 
While the combination of these adjuvants synergized in BMDC activation, it only translated 
into a small increase in T cell activation, in vitro. These results demonstrated a stronger efficacy of 
NP-CpG-B alone to activate DCs compared to the TLR-7/8, and so, we wanted to determine if the 
addition of PS-CL075 would increase the efficacy of the TLR-9 vaccine in an orthotopical tumor 
model, in vivo. The dose of NP-CpG-B used for the vaccine was considered very low but 
unfortunately, the conjugation efficiency did not permit to inject a dose higher than 1 μg/mouse 
whereas the dose of PS-CL075 tested was 15 μg/mouse, which corresponds to what had been used 
previously in the combination of PS-MPLA + PS-CL075, in vivo. Briefly, mice were inoculated 
with B16-OVA in the right dorsal scapular skin before vaccination in the forelimb draining the 
TdLN 7 days post-inoculation (Fig.3.8.A). Although no significant difference in tumor growth was 
observed between treatments, a small delay, for the co-injected adjuvanted-particles, was detected 
(Fig.3.8.B). In addition three mice died for unknown reasons (red arrow), which, in the case of the 
PBS treated group, decreased its tumor growth curve, matching the other groups, which would not 
be the case if they had survive (Fig.3.8.B, bottom left). A significant increase in CD8+ T cells in 
addition to a decrease in CD4+ Treg cells were observed, in the tumor microenvironment, when mice 
were vaccinated compared to the negative control group (Fig.3.8.C, left & middle). The ratio of 
activated CD8+ T cells over CD4+ Treg cells was slightly increased when the treatment contained 
both adjuvants compared to NP-CpG-B alone but not significantly (Fig.3.8.C, right). Finally the 
percentage in SIINFEKL-specific CD8+ T cells, as well as CD25+ CD8+ T cells, showed similar 
results independently of the addition of PS-CL075 to NP-CpG-B (Fig.3.8.D). 
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Figure 3.8 PS-CL075 addition to NP-CpG-B vaccine did not delay tumor growth or increase the T cell immune response. 2.5 
x 105 B16-OVA cells were inoculated i.d. in the right dorsal scapular skin before vaccinating mice on day 7 i.d in the forelimb 
draining to the same lymph node as the tumor (A) Experimental timeline, groups and dose. (B) Overall (Top), and individual 
(Bottom), tumor growth. (C) Proportion of CD8+ T cells, CD4+ Treg cells and the ratio of both in the tumor microenvironments. (D) 
SIINFEKL-specific CD8+ T cells population in the spleen quantified by SIINFEKL-MHC-I pentamer staining. Error bars indicate 
SEM for (B) and SD for (C-D) the other. N = 3-5 mice per groups. *P < 0.05. 
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Finally, the T cell immune response was assessed by reactivating the spleen and the tumor-
draining lymph nodes with MHC-I or MHC-II dominant tumor antigens. Although vaccinated mice 
had similar levels of granzyme B, independently of the treatment, a large decrease in IFN? was 
observed when PS-CL075 was co-administered (Fig.3.9.A). The restimulation with the SIINFEKL 
peptide showed identical percentage of TNF?+IFN?+ CD8+ T cells for both vaccines, which were 
significantly higher than the negative control group (Fig.3.9.B, left). A small increase in double 
positive CD4+ T cells was observed for vaccinated groups compared to PBS treated mice 
(Fig.3.9.B, middle) and in addition, the reactivation of CD8+ T cells with endogenous antigens, 
TRP-2 and gp100, showed no significant increase in TNF? positive cells compared to the PBS 
treated groups, but a small trend was observed (Fig.3.9.B, right). The TdLN showed no difference, 
in granzyme B secretion or polyfunctional T cells, between NP-CpG-B alone or combined to PS-
CL075 (Fig.3.9.C-D). Inversely as seen in the spleen, the production of IFN? was similar between 
both vaccines and significantly increased compared to PBS treated groups (Fig.3.9.C). Finally, no 
difference between vaccinated groups was observed when reactivated with endogenous B16-F10 
peptides. 
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Figure 3.9 The addition of PS-CL075 to NP-CpG-B did not improve the T cells immune response in the spleen or TdLN. 2.5 x 
105 B16-OVA cells were inoculated i.d. in the right scapular dorsal skin. Mice were vaccinated, i.d. in the forelimb draining TdLN, 7 
days post tumor inoculation. The cytokine secretion quantification (A & C) was done after 4 days incubation before collecting the 
supernatant whereas polyfunctional T cells quantification by flow cytometry was performed after 6 h incubation (B & D). (A & C) 
Granzyme B and IFN? concentration in the supernatant after SIINFEKL reactivation in the spleen and TdLN, respectively. (B & D) 
Polyfunctionality quantification in the spleen and TdLN. Left, was the proportion of TNF?+ IFN?+ CD8+ T cells. Middle, was the 
proportion of TNF?+ IFN?+ CD4+ T cells and right was TNF?+ CD8+ T cells. Error bars are SD and N = 5 mice per groups. *P < 
0.05 and **P<0.01. 
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Although synergistic effects were observed for several PS-MPLA and NP-CpG-B 
combination in BMDCs activation, it did not translate in a strong T cell activation, 
in vitro 
The final adjuvants combination tested for synergistic effect was NP-CpG-B with PS-MPLA, 
at different dose. As done in the previous adjuvant combination, the same three doses of each 
adjuvant were tested in combination with one another. As a reminder, NP-CpG-B concentrations 
tested was 1, 0.1 and 0.01 μM and PS-MPLA was 600, 60 and 6 nM. Interestingly, the highest dose 
of NP-CpG-B tested in combination with PS-MPLA induced synergistic effect for IL12p70 
production but not for IL6 and was even almost inexistent for TNF? (Fig.3.10.A). The medium 
dose of NP-CpG-B also induced synergistic effect, with an increase effect at higher PS-MPLA 
dose, in all cytokines tested. Finally the low dose of NP-CpG-B only had an effect with a high dose 
of PS-MPLA for IL12p70 and IL6 secretion but not TNF?. Concerning the co-stimulatory markers, 
a small increase in expression was observed when combining the different adjuvants but the effect 
were not considered synergistic (Fig.3.10.B). 
 
 
 
Figure 3.10 Synergistic effect was observed in cytokines secretion for several different adjuvant combinations. (A) Cytokines 
concentration after BMDCs activation. BMDCs were incubated in a 96-well plate, with different doses of NP-CpG-B and PS-MPLA, 
for 24 h before quantifying the supernatant by ELISA. (B) BMDCs activation and costimulatory expression. BMDCs were incubated 
with the same treatments as in (A) for 6 h before staining for flow cytometry analysis. Results are representative of two independent 
repeats, and * represent synergistic effects observed for that specific combination. 
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Based on the results obtained for the BMDC activation experiment, CD4+ and CD8+ T cells 
co-culture were performed to determine if the activation of DC increase the activation of T cells, in 
vitro. The dose tested were 0.1 μM NP-CpG-B mixed with any dose of PS-MPLA since they 
induced higher cytokines secretions than with a higher, or a lower, dose of NP-CpG-B. BMDCs 
were incubated overnight with different adjuvant treatments and 5 μM OVA before only removing 
the adjuvants and adding the OT-I or OT-II cells at a 1:10 ratio with BMDCs. Unfortunately, 
neither the CD8+ nor the CD4+ T cells co-culture showed an increase in activation when treated 
with the different adjuvant combinations. Interestingly, the addition of PS-MPLA to NP-CpG-B did 
not increase the production of granzyme B or IFN?, even if PS-MPLA, alone, had an increase in the 
secretion at a dose dependent manner (Fig.3.10.A, left & middle). Inversely, the combination of 
both adjuvants followed the same curve as PS-MPLA alone for the secretion of IL2 (Fig.3.11.A, 
right). The proliferation index and expression of CD25 did not increase when both adjuvants were 
combined (Fig.3.11.B, left & middle) and it slightly decreased for the percentage of IFN?+ CD8+ T 
cells (Fig.3.11.B, right). The CD4+ T cell co-cultures showed the same trend as CD8+ T cells for 
IFN? and IL2 cytokines secretion (Fig.3.11.C). Again, no differences were observed in proliferation 
index (Fig.3.11.D, left), the expression of IL2 (Fig.3.11.D, right) and only a slight increase in IFN?+ 
CD4+ T cells when adjuvants were combined (Fig.3.11.D, middle). 
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Figure 3.11 No synergistic effects were observed in CD8+ or CD4+ T cells co-cultures with the different adjuvant 
combinations tested. 15’000 BMDCs were activated overnight with OVA and different adjuvant combinations before removing the 
adjuvant formulation and adding CFSE labeled OT-I or OT-II. After three days, the supernatant was collected for cytokine 
quantification, by ELISA, and cells were staining for flow cytometry analysis. (A) Granzyme B, IFN? and IL2 cytokines 
concentrations.in the supernatant. (B) CD8+ T cells activation. The proliferation, activation markers and cytokine production was 
quantified by flow cytometry. (C) IFN? and IL2 cytokines concentrations in the supernatant. (D) CD4+ T cells activation. 
Proliferation and activation markers quantification by flow cytometry. Results are representative of three independent repeats, and * 
represent synergistic effects observed for that specific combination. 
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A decrease in tumor growth was observed when both adjuvants were co-injected 
although the T cell immune response was similar  
 
The in vitro experiment showed synergistic effect for several different adjuvant combinations, 
but the one inducing the most effect in BMDCs cytokine production was 0.1 μM NP-CpG-B with 
0.6 μM PS-MPLA. This combination represents a 1:6 ratio between the two adjuvants, which was 
used for the following in vivo experiment in a tumor model setting. Briefly, mice were inoculated 
with B16-OVA cells on the upper right side of the back and 7 days post-inoculation, they were 
vaccinated with the different treatments (Fig.3.12.A). The tumor growth for the mice co-injected 
with both adjuvants clearly showed a decrease compared to NP-CpG-B alone (Fig.3.12.B). 
Unfortunately, two mice in the control groups died for unknown reason explaining the lower tumor 
growth curve than usual. Although a decrease in tumor growth was observed when both adjuvants 
were administered, a higher percentage of CD8+ T cells were present, in the tumor 
microenvironment, (Fig.3.12.C, left) and SIINFEKL-specific CD8+ T cells, in the spleen, were 
detected when only NP-CpG-B was injected (Fig.3.12.D). Vaccination also induced lower 
proportion of CD4+ Treg and a higher ratio of activated CD8+ T cell versus CD4+ Treg cells, in the 
tumor, compared to the PBS treated group (Fig.3.12.C, middle & right). 
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Figure 3.12 PS-MPLA addition to NP-CpG-B vaccine delayed tumor growth but did not increase SIINFEKL-specific CD8+ T 
cells. 2.5 x 105 B16-OVA cells were inoculated i.d. in the right dorsal scapular skin. Mice were vaccinated, i.d. in the hock draining 
to the same lymph node as the tumor, 7 days post tumor inoculation, before sacrificing the mice on day 14. (A) Experimental 
timeline, groups and dose. (B) Overall (Top), and individual (Bottom), tumor growth. (C) Proportion of CD8+ T cells, CD4+ Treg cells 
and the ratio of both in the tumor microenvironments. (D) SIINFEKL-specific CD8+ T cells population in the spleen quantified by 
SIINFEKL-MHC-I pentamer staining. Error bars indicate SEM for (A) and SD for all the other. N = 5 mice per groups. *P < 0.05 
and **P<0.01. 
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The T cell immune response was quantified into more detail for the spleen and tumor-draining 
lymph node by reactivating CD8+or CD4+ T cells with different MHC-I/II peptides. The spleen 
showed similar trends as in the tumor microenvironment where, mice vaccinated with only NP-
CpG-B induced higher T cells response compared to the co-injected vaccine or the PBS treated 
control. Granzyme B and IFN? concentration in the supernatant were slightly lower when both 
adjuvants were injected compared to NP-CpG-B alone but was still higher than the negative control 
(Fig.3.13.A).  Finally, the vaccination increased the proportion of polyfunctional T cells compared 
to PBS treated mice (Fig.3.13.B, left & middle) but only a small trend was detected when cells were 
reactivated with endogenous CD8+ T cell specific antigens (Fig.3.13.B, right). Concerning the 
tumor-draining lymph node, similar trends as in the spleen were observed but in a lower proportion. 
A significant difference was detected between NP-CpG-B vaccine and PBS for the concentration of 
granzyme B concentration and IFN? (Fig.3.13.C). Interestingly, both vaccines tested were 
significantly increased compared to the negative control for TNF?+IFN?+ CD8+ and CD4+ T cells 
but not when endogenous antigens were used for the restimulation (Fig.3.13.D). 
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Figure 3.13 The addition of PS-MPLA to NP-CpG-B did not increase the T cells immune response. 2.5 x 105 B16-OVA cells 
were inoculated i.d. in the right scapular dorsal skin. Mice were vaccinated, i.d. in the hock draining TdLN, 7 days post tumor 
inoculation. The cytokine secretion quantification (A & C) was done after 4 days incubation before collecting the supernatant 
whereas polyfunctional T cells quantification by flow cytometry was performed after 6 h incubation (B & D). (A & C) Granzyme B 
and IFN? concentration in the supernatant after SIINFEKL reactivation in the spleen and TdLN, respectively. (B & D) 
Polyfunctionality quantification in the spleen and TdLN. Left, was the proportion of TNF?+IFN?+ CD8+ T cells. Middle, was the 
proportion of TNF?+IFN?+ CD4+ T cells and right was TNF?+ CD8+ T cells. Error bars are SD and N = 5 mice per groups. *P < 0.05 
and **P<0.01. 
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3.5. Discussion 
 
Overall, we were able to determine which adjuvant combination synergize to increase 
BMDCs activation, in vitro, as well as some insight on T cell maturation, in vitro and in vivo. The 
ideas of combining different adjuvants to increase the immune response, while lowering the dose, 
was a very appealing strategy but since a multitude of pathways are involved for the upregulation of 
cytokines, it was very difficult to obtain a clear response in synergistic effect for the T cell response 
112. 
 
The first combination tested was the TLR-4 agonist, PS-MPLA, with the TLR-7/8 agonist, 
PS-CL075. Several different combinations tested induced a 2- to 4-fold synergistic effect in TNF?, 
and IL12p70 production, and up to a 24-fold increase for IL10 secretion when BMDCs were 
activated. Surprisingly, at a fixed concentration of PS-MPLA, the highest dose of PS-CL075 tested 
had similar levels of proinflammatory cytokines compared to a lower dose of the TLR-7/8 agonist 
and a strong increase in IL10 production, which correlates with an overactivation of BMDCs 
(Fig.3.2.A). Indeed, this cytokine is an immunosuppressive molecule that can inhibit 
proinflammatory response in order to prevent tissue damage due to inflammation 113, 114. With this 
information, it was possible to assume that the highest dose of PS-CL075 with PS-MPLA 
overstimulated BMDCs leading to the secretion of IL10 to control the inflammatory response. Co-
stimulatory molecules were increased in a dose dependent manner when both adjuvants were 
combined but not in a synergistic way. The decrease in granzyme B and IFN? cytokines for the 
CD8+ T cell co-culture, as well as, the absence of difference in activation markers correlated with 
the increase in IL10 secretion produced by BMDCs (Fig.3.3.A) 115. Interestingly, the CD4+ T cells 
co-culture showed a small increase in IFN?+ and IL2+ T cells, which was not the case for the CD8+ 
T cells. It has been demonstrated that IL10 can directly inhibit CD8+ T cells antigen sensitivity, thus 
dampening its activation, which is a possible explanation for the decrease IFN? secretion observed 
115, 116. In addition, a subset of CD4+ TH1 cells is known to be capable of producing not only IFN? 
but also IL10, indicating the possibility of having IFN? as well as IL10 secreted simultaneously 117. 
For the in vivo setting, the injection of PS-MPLA alone produced the highest magnitude of 
activated T cells, in term of granzyme B and IFN? (Fig.3.5), while adding PS-CL075 reduced their 
productions. Surprisingly, the percentage of SIINFEKL-specific CD8+ T cell was similar or slightly 
higher when the TLR-7/8 was added to PS-MPLA (Fig.3.4.C). This would suggest that either the 
restimulation induced the exhaustion of T cells or the combination itself overactivated them, 
thereby causing them to go into exhaustion or senescence too quickly. In addition, CD4+ T cells are 
known to express TLR-7/8 which when activated induce the secretion of IFN? 118, increasing 
furthermore the immune activation of T cells. A solution to determine if the system was 
62 
 
overactivated would be to reduce the amount of PS-MPLA in combination with PS-CL075 and see 
if the immune response is increased since only one dose of PS-MPLA was tested. This 
demonstrates the fine equilibrium between activation and exhaustion when creating a vaccine. 
 
The second combination tested was NP-CpG-B, a TLR-9 agonist, with PS-CL075, a TLR-7/8 
agonist and the only synergistic effects observed were in the production of TNF? by BMDCs, in 
vitro (Fig.3.6.A). A possible explanation for the small synergistic effect (only 2-fold) would be that 
they both activate the NF-?B pathway removing the advantage of activating several pathways. The 
decrease in cytokine secretion for PS-CL075 with 1 μM NP-CpG-B, without increasing the 
production of IL10 (data not shown) could be due to a toxicity effect from the dose of the NP-CpG-
B used. Indeed, the same concentration of free CpG-B also induced lower cytokine secretion 
compared to a lower dose. In the previous chapter, the flow cytometry analysis did not show an 
increase in cell death, which would indicate toxicity of the treatment, compared to the other groups 
(data not shown) but these results were obtained after only 6 h activation compared to the 24 h 
experiments for cytokine quantification. Surprisingly, the addition of PS-CL075, to 0.01 μM NP-
CpG-B, had an additive effect on the co-stimulatory expression, in a dose dependent manner but did 
not induce higher cytokine secretion (Fig.3.6.B). This suggested that a stronger activation was 
needed for cells to secrete cytokines whereas only a small one was required for the expression of 
co-stimulatory molecules. This would also explain why the other adjuvant combination did not 
show synergistic effect for BMDC by flow cytometry since they already showed stronger 
synergistic effect than the present combination. The co-culture experiments only showed an 
enhance IL2 secretion by CD8+ T cells (Fig.3.7.A, right) but no increase for the other cytokine. It 
was shown by Shannon et al that IL2 producing CD8+ T cells preferentially survive and develop 
memory traits, which is an important factor for the development of a long lasting immune response 
119. Overall, the dose of NP-CpG-B used for the treatments were generally enough to induce a 
strong activation of CD4+ and CD8+ T cells and, only a small increase in IL2 secretion when PS-
CL075 was added to the TLR-9 agonist. A possible explanation was that CpG-B had a stronger 
inherent activation property than CL075. In vivo vaccination of both adjuvants did not significantly 
delay tumor growth and the addition of PS-CL075 had no visible effect on the immune response for 
antigen-specific CD8+ T cells (Fig.3.8.B). The CD4+ and CD8+ T cells restimulation, in the spleen 
and TdLN showed identical trend, with an increase in polyfunctional T cells when mice were 
vaccinated but no differences within them (Fig.3.9.B-C). As seen in the previous adjuvant 
combination, a decrease in IFN? secretion was observed in the spleen when PS-CL075 was co-
administered with NP-CpG-B (Fig.3.9.A, right). Overall no strong synergistic effect or increase in 
the immune response was detected when combining both adjuvants. 
 
63 
 
The final combination tested was PS-MPLA with NP-CpG-B and similar synergistic effects 
were observed in BMDCs activation for proinflammatory cytokines as when the PS-MPLA/PS-
CL075 combination was tested. The increase of IL10 was also detected in a dose dependent manner 
when adjuvants were combined, which would explain the absence of TNF? secretion when 0.1 μM 
NP-CpG-B was combined with PS-MPLA (Fig.3.10.A). As for the previous combination, no 
synergistic effects were observed for BMDCs co-stimulatory molecules (Fig.3.10.B) and co-culture 
experiments showed again a decrease in IFN? secretions, as well as no significant differences 
between the different formulations tested. In vivo, a delay in tumor growth as well as a decrease in 
tumor size was observed when mice where vaccinated with both adjuvants (Fig.3.12.B). 
Surprisingly, these results did not translate in an increased percentage of antigen-specific CD8+ T 
cells, in the spleen, or CD8+ T cells infiltrate in the tumor (Fig.3.12.C), which was even lower than 
the mice receiving only NP-CpG-B in the vaccine. The restimulation of the spleen and the tumor-
draining lymph node showed similar trends as previously, were a higher proportion of cytokine 
production (Fig.3.13. A & C) was detected when only the TLR-9 agonist was used. Even so no 
difference in T cell immune response was observed, a clear decrease in tumor growth was present.  
 
In this study, we showed that combinatorial delivery of adjuvanted-nanoparticles targeting the 
TLR-4, TLR-7/8, and TLR-9 pathways can lead to synergistic effects in terms of DC activation and 
subsequently, T cell activation. In vitro screens identified promising formulations that optimized 
these measures, which are thought to generally correlate well with tumor killing, but in an 
orthotopic implantable model of aggressive melanoma, this was not always the case. In these 
studies, only the combination of TLR-4 with TLR-9 agonist achieved synergistic effects for 
BMDCs activation, in vitro, as well as a decrease in tumor growth, in vivo. It was notable that 
during in vitro screening, the TLR-4/TLR-9 co-targeting strategy was the only one among the three 
tested that produced strong synergistic effects in improving granzyme B and IFN? expression by 
CD8+ T cells. On the other hand, all three combinations produced similar trends in terms of 
increasing TNF? and IL-12p70 secretion by BMDCs and small additive but insignificant effects on 
BMDC surface expression of co-stimulatory molecules. This suggests that future screening of 
adjuvant combinations for optimal formulations used for therapeutic tumor vaccination should 
continue to use granzyme B and IFN? upregulation as a predictive marker for therapeutic efficacy. 
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Chapter 4 
4.  
Radiotherapy in combination with an adjuvant-based 
vaccine delays tumor growth 
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4.1. Abstract 
 
Over the past decades an increasing number of studies were focused on understanding the 
effects of radiotherapy on the tumor microenvironment and the tumor-specific immune response. 
Since it has now been established that ionizing radiation does not only directly affect tumor cell 
proliferation and survival but can also promote the anti-tumor immune response, researchers are 
testing the effect of combining radiation with different forms of cancer immunotherapy. 
 
We hypothesized that a reduction in tumor growth, as well as an increase in survival, could be 
obtained when combining localized tumor radiotherapy with our adjuvanted-nanoparticulate 
vaccine, since it is known that the tumor-draining lymph node (TdLN) is a primary site of T cell 
priming following tumor irradiation. Before testing our hypothesis, different parameters, such as the 
vaccination schedule, the injection site and the organ targeted by the vaccine were tested to 
determine their effect on the immune response when combined with radiotherapy. We first 
demonstrated that, although, the vaccine was administered in the forelimb draining the TdLN and 
not intratumorally, an enhance T cell immune response was obtained. In addition, a single 
vaccination induced a stronger response compared to a fractionated vaccine schedule. Interestingly, 
the vaccination of free CpG-B subcutaneous injected in the forelimb draining to a non-TdLN 
induced a strong IFN? secretion in the spleen and a decrease of tumor growth compared to the 
targeting of the TdLN, it did not increase the percentage of antigen-specific CD8+ T cells, or 
increase the immune response in the tumor microenvironment and the draining lymph node. The 
last parameter tested was the difference in tumor growth and survival when mice were vaccinated 
with NP-CpG-B intradermally or intratumorally. The results demonstrated no difference between 
both injection sites, although some complications, due to the ulceration of the tumor which occurred 
for the intratumoral injection. Finally, the combination with radiotherapy and the co-injection of 
PS-MPLA and NP-CpG-B induced a decrease in tumor growth and an increase in survival. 
Consistently, CD8+ and CD4+ T cells were increased in the tumor site and secreted higher levels of 
IL2 in the TdLN following ex vivo reactivation. Overall the addition of adjuvant vaccine increased 
the survival of tumor-bearing mice with a trend towards increased IL2 and IFN? secretion, but the 
exact mechanism by which the tumor growth was decreased has to be further studied. 
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4.2. Introduction 
 
Although radiotherapy is traditionally used to directly kill tumor cells, more recent studies 
have shown that irradiation also has immunomodulatory proprieties and affects different cell 
populations in the tumor microenvironment 120. Indeed, it was demonstrated that not only tumor 
cells die, but antigen-presenting cells (APCs), T cells, endothelial cells and stromal cells undergo 
apoptosis after local irradiation 121. Due to the radiosensitivity of lymphocytes and antigen-
presenting cells to ionizing radiation, radiotherapy was thought to induce a suppressive effect on the 
immune system 122. However, over the past two decades, several studies have shown the ability of 
irradiation to induce an immune response, depending on the dose, the frequency and the irradiated 
volume 120, 123, 124. 
 
It was thought that a high dose of radiation induces enhanced double-stranded breakage, 
which leads to increased tumor cell death, release of tumor antigens, and IFN? secretions, thus 
promoting activation of cytotoxic CD8+ T cells. Lugade et al compared a single dose of 15 Gy 
radiations with a fractionated radiotherapy, 3 x 5 Gy, and showed higher APCs and CD8+ T cells 
activation in the tumor-draining lymph node, as well as an increase in IFN?-secreting cells when 
irradiated with the high dose 125. It has also been demonstrated that a 20 Gy dose induced tumor 
rejection of B16-F10 in immunocompetent mice but not immunodeficient, proving the ability of 
irradiation to mount an anti-tumor response 59. Furthermore, depending on the tumor type, the 
efficacy of the dose and schedule can influence the immune response. Indeed a single high-dose 
radiation induced a better immune response than fractionated in B16-F10 melanoma and, inversely, 
a fractionated dose (3 x 8 Gy) combined to CTLA-4 antibody treatment was more potent in murine 
breast cancer than an ablative dose 126. It was postulated that T cell priming occurred in the tumor 
draining lymph node after DC-mediated cross-presentation of tumor antigens. Moreover, 
radiotherapy treatment induces the secretion of a multitude of cytokines, an important one for 
radiation-induced T cell priming being IFN? 127. The presence of radiotherapy-induced IFN? 
secretion in the tumor microenvironment was shown to increase the percentage of T cells 
trafficking to the tumor through the upregulation of VCAM-1 in the tumor vasculature and 
chemoattractant MIG and IP-10, thus reducing tumor growth 128. 
 
Although radiotherapy is able to naturally induce an immune response against tumors, 
immune-mediated abscopal responses (i.e. regression of secondary tumors distant from the treated 
primary tumor site) remain rare. Therefore, combination with immunotherapy could be a promising 
option to improve the outcome of the patient 12. Several clinical trials demonstrated the efficacy of 
increasing the pool of dendritic cells in the tumor after radiotherapy by injecting up to 107 cells 
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intratumorally and showed higher percentage of tumor-infiltrated CD8+ T cells as well as antigen-
specific T cells in prostate cancer 129, carcinoma 130 and refractory hepatoma 131. The activation of 
DCs can also be done with the use of TLR agonist. Brody et al reported a 27% increase response 
rate when patients with low-grade B cell lymphoma were irradiated with a fractionated low-dose (2 
x 4 Gy) combined to CpG-B (30 mg), injected intratumorally 132. A follow-up of this study, in 
mycosis fungoides showed a 33% response rate with a reduction of CD25+ T cells 133. An ongoing 
clinical trial using TLR-4, glycopyranosyl lipid A, with six fractions of radiotherapy for metastatic 
sarcoma (ClinicalTrials.gov identifier: NCT02180698) as well as a TLR-7 agonist in breast cancer 
metastases in the skin (ClinicalTrials.gov identifier: NCT01421017) are also being tested to 
determine their effect when added to ionizing radiation. Other approaches combining radiotherapy 
with checkpoint blockade (CTLA-4 or PD-1), co-stimulation (OX40 agonist), chemotherapy 
(cyclophosphamide) or even cytokines (IL2, IFN?) are being investigated in clinical trials after 
successfully demonstrating synergistic effect in mice.  
 
Overall, an increase response rate was observed when radiotherapy was combined with 
immunotherapy. However, in most of these studies, TLR agonists were either applied topically on 
the tumor site or injected intratumorally. We hypothesized that combining PS-MPLA and NP-CpG-
B with a single high dose of localized ionizing radiation would result in an enhanced therapeutic 
efficacy compared to either irradiation or vaccination alone. The advantage of our vaccine would be 
the targeting of the lymph node rather than the tumor, since DCs prime the immune response 
mainly in the TdLNs.  In addition, while antigen presenting cells and lymphocytes within the tumor 
site may undergo apoptosis and reduced proliferation following localized tumor radiotherapy (due 
to their radiosentitivity), the pool of DCs and lymphocytes in the TdLNs is protected from the direct 
effects of radiation and thus represents an ideal target for vaccination in this context. 
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4.3. Materials and Methods 
Mice 
All mice used in experiments were C57BL/6 female 8-12 weeks old, purchased from Harlan 
(France) or Jackson laboratory (USA). All procedures were performed in compliance with the 
Veterinary Authority of the Canton of Vaud (Switzerland) according to Swiss laws and the 
Institutional Animal Care and Use Committee at the University of Chicago (USA) 
Cell line 
The melanoma B16-F10 expressing ovalbumin (B16-OVA) cells line was gifted from 
Bertrand Huard (University of Geneva, Switzerland) and was maintained in high glucose DMEM 
(Gibco, Waltham, Massachusetts, USA; Catalog # 11995) supplemented with 10% FBS. 
Materials, reagents and antibodies 
Reagent grade chemicals were purchased from Sigma-Aldrich (Saint Louis, MO, USA) unless 
noted otherwise. All adjuvants, except for CpG-B, were purchased from InvivoGen (San Diego, 
CA, USA). The modified 5’SPO3-CpG-B (5’-TCCATGACGTTCCTGACGTT-3’) was purchased 
from Microsynth (Balgach, Switzerland) or TriLink Biotechnologies (San Diego, CA, USA).  
 
Anti-mouse antibodies CD80 (clone 16-10A1), CD86 (clone GL1), CD40 (clone 3/23), CD8 
(clone 53-6.7), CD4 (clone RM4-5), IFN? (XMG1.2), CD25 (clone PC61), IL2 (clone JES6-5H4), 
CD45 (clone 30-F11), CD3 (clone 145-2C11), FoxP3 (clone MF23), TNF? (MP6-XT22), CD62L 
(clone MEL-14), CD44 (clone IM7) and fixable live/dead were purchased from ThermoFisher 
Scientific (Waltham, MA, USA). The SIINFEKL-specific pentamer, PE-labeled H-2Kb/OVA257-264 
was purchased from Proimmune (Oxford, UK). 
Tumor inoculation and immunizations 
An orthotopic injectable melanoma model was employed through the intradermal injection of 
B16-OVA tumor cells. To expose the injection site, healthy adult wild-type C57BL/6 mice were 
anesthetized with isoflurane (3.5%), and dorsal scapular skin on the mouse’s right side after shaving 
and disinfecting the area. 2.5 x 105 B16-OVA tumor cells in 30-45 μL of 0.9% saline solution were 
delivered intradermally at this site. All nanoparticle adjuvants were prepared as explained in the 
previous chapter, and conformed for low endotoxins levels by HEK-blueTM TLR-4 assay. The 
formulations were mixed right before the vaccination, which was administered i.d. in the forelimb, 
draining the same lymph node as the tumor. The maximum volume injected was 30 μL. 
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Starting on day 4 post-inoculation, tumors were measured every other day with digital 
calipers and the volume was calculated using an ellipsoidal equation: ? ? ????
?
??
?
? ?
?
? , where L 
is the length, W is the width and H is the height. 
In vivo tumor irradiation 
Mice were irradiated with 15 Gy using the RadSource Technologies X-ray RS-2000 
biological irradiator operating at 160 kVp and 25 mA. Mice were anesthetized with a solution of 
ketamine/xylazine administered intraperitoneal and their entire body, except for the tumor, was 
placed under a lead shield to protect from irradiation. If necessary, the process was repeated 7 days 
after the first irradiation.  
Whole organ/tumor processing into single-cell suspensions 
To analyze immune responses within specific anatomic compartments, the tumor-draining 
lymph node, the spleen and the tumor were harvested and processed into single-cell suspensions for 
flow cytometry. For the TdLN and the spleen, cell suspensions were obtained by mechanically 
disrupting the organ and rinsing with PBS, or IMDM, through a 0.7 μm cell strainer (CorningTM, 
NY, USA), and then centrifuging the resulting cell suspension at 1500 rpm for 5 min. The TdLN 
was then resuspended in IMDM supplemented with 10% FBS, 102 U/mL penicillin, 102 ?g/mL 
streptomycin and 20 μM 2-mercaptoethanol (Full media) and counted. Splenocytes were first 
washed in a hypotonic solution of ammonium chloride-potassium bicarbonate (ACK) for 2 min to 
remove red blood cells, prior to centrifugation at 1500 rpm for 5 min, resuspension in full media 
and counting. The tumor cell suspension was obtained by adapting a protocol from Broggi et al 110. 
Briefly, the tumor was minced, and then digested in digestion media (DMEM + 2% FBS + 1.2 mM 
CaCl2 + 102 U/mL penicillin + 102 ?g/mL streptomycin) supplemented with 1 mg/mL Collagenase 
IV and 40 μg/mL DNAse I (Worthington Biochemical Corp, Lakewood, New Jersey, USA). This 
suspension was stirred at 37°C for 30 min, further disrupted by repetitively pipetting 100x, and then 
filtered through a 70 μm strainer. The remaining undigested tumor fragments were further digested 
at 37°C for 1 h in a second digestion mix consisting of digestion buffer supplemented with 3.5 
mg/mL Collagenase D and 40 μg/mL DNAse I.  The tumor fragments were further mechanically 
disrupted through repetitive pipetting them 100x. The enzymes were quenched through the addition 
of EDTA to a final concentration of 2.5 mM, and then the cell suspensions were filtered through a 
70 μm strainer and combined with the cells from the first digestion step. As tumors may contain a 
significant amount of blood, the resulting cell suspensions were treated similarly to the splenocytes 
described above before they were resuspended in full media and counted. As for the spleen, red 
blood cells were lysed using the same protocol. Finally, the cell suspension was resuspended in full 
media and counted.  
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Blood processing 
Blood were collected in EDTA coated tubes and centrifuged at 1500 rpm for 5 min. The 
plasma was stored at -20°C and red blood cells were lysed with an ACK solution and resuspended 
in full media before staining them for flow cytometry. 
Ex vivo restimulation 
For the reactivation of antigen-specific T cells in TdLNs and spleens, these organs were 
processed into single-cell suspensions as described above, and then plated in U-bottom 96-well 
plates at up to 2 ? 106 cells/well. The cells were incubated at 37°C in a 5% CO2 incubator with 2 
μg/mL of antigenic peptide in full medium. For cytokine quantification by ELISA, supernatants 
were collected following 4 days of incubation, whereas for flow cytometry analysis, cells were 
incubated for 3 h prior to halting cytokine export through the addition of brefeldin A to a final 
concentration of 5 μg/mL, followed by incubation for an additional 3h before harvest.  To re-
stimulate antigen-specific CD8+ T cells, the MHC-I-dominant peptides OVA257-264 (SIINFEKL), 
whereas CD4+ T cells were reactivated with OVA323-339. 
Flow cytometry 
Cell suspensions were centrifuged and washed with 1x PBS, and then incubated with a fixable 
live/dead at 4°C for 15 min before washing again once with PBS. Antigen-specific T cells were 
detected via pentamer staining, which was performed by incubating cells at room temperature in a 
solution of 1x PBS supplemented with 2% FBS (staining buffer), for 20-30 min. For surface 
staining, a cocktail of antibody was diluted in staining buffer and incubated at 4°C for 15 min. 
Intracellular staining and intranuclear staining were performed with the BD cytofix/cytopermTM Kit 
or FoxP3 staining kit, respectively, according to the manufacturer’s instructions. Finally, the cells 
were washed with staining buffer and stored in the same buffer for data collection. 
ELISA 
Cytokines detection and quantification were performed with Ready-SET-Go! ELISA kits 
purchased from ThermoFisher Scientific and used according to the manufacturer’s instructions. 
Flow cytometry 
Flow cytometry was performed using either a CyAnTM ADP (Beckman Coulter, Brea, CA 
USA) or a BD LSRFortessaTM (BD Biosciences, San Jose, CA, USA). The data obtained were 
analyzed with FowJo (v.10, FlowJo LLC, Ashland, OR, USA). Graphs and statistical analysis were 
done using the GraphPad Prism 7 Software (GraphPad Software Inc, La Jolla, CA, USA).  
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Statistical significance between the different groups were determined with a one-way analysis of 
variance (ANOVA) followed by a Bonferroni post-test correction. * and ** indicate P values less 
than 0.05 and 0.01, respectively. 
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4.4. Results 
 
As said previously, the final goal of this study was to test the combination of our adjuvanted-
nanoparticle vaccine with radiotherapy and, in order to obtain the strongest immune response 
against B16-OVA with our treatment, different parameters were tested, beforehand. 
 
The combination of adjuvant vaccination with radiotherapy enhance the T cell 
immune response and delayed tumor growth 
The main purpose of this experiment was to determine if the immune response could be 
enhanced when vaccination in the forelimb draining the TdLN was added to radiotherapy and, in a 
second time, if the vaccination schedule influenced the response. Since all the studies mentioned 
previously injected the treatment intratumorally, it was important to determine if similar results 
could be obtained when injecting in the forelimb draining the TdLN. As discussed in the first 
chapter, the ionizing radiation can induce immunogenic cell death through several different 
mechanisms, which increase the uptake of antigens by DCs. The time for dendritic cells to reach the 
tumor-draining lymph node is not exactly known and so two different vaccination schedules were 
tested. The first group was vaccinated only once with 20 μg CpG-B whereas the second group 
received two injections of 10 μg CpG-B, with a 3 days gap between the first and second injection 
(Fig.4.1.A). This experiment was performed with free CpG-B, rather than with NP-CpG-B, to have 
the possibility to inject a higher dose. The overall tumor growth curve did not show any significant 
difference between groups (Fig.4.1.B, top & bottom left). Mice treated 4 times with CpG-B had 
similar tumor growth for most of the experiment but on day 17, the tumor grew much faster, than 
the other treatments (Fig.4.2, bottom middle). The isolated cell suspension from the spleen showed 
similar percentage of SIINFEKL-specific CD8+ T cell in all three groups (Fig.4.1.C, left) but a 
significant increase in CD44+CD62L- CD8+, and CD4+, T cells were observed for the vaccinated 
mice, independently of the schedule (Fig.4.1.C, middle & right). Concerning the tumor 
microenvironment, similar trends in CD8+ (Fig.4.1.D) and CD4+ T cells (Fig.4.1.E) were observed. 
No difference in the percentage of T cells (Fig.4.1.D & E, left) or effector (Fig.4.1.D & E, middle) 
were detected between treatments but a decrease in PD-1+ T cells were present when mice were 
vaccinated with a single dose compared to the PBS-treated group (Fig.4.1.D & E, right).  
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Figure 4.1 The T cell population was similar in the tumor microenvironment between both schedules. 2.5 x 105 B16-
OVA tumor cells were inoculated in the right scapular dorsal skin before irradiating them with 15 Gy on day 7. The “ 2 x
20 μg CpG-B” group was vaccinated on days 7 and 14 whereas the “4 x 10 μg CpG-B” were injected on days 7, 10, 14 and
17. Finally, mice were sacrificed on day 19 post-tumor inoculation to quantify the immune response. (A) Timeline and 
treatment groups. (B) Average, top, and individual, bottom, tumor growth. (C) T cell population in the spleen. Left is the
percentage of SIINFEKL-specific CD8+ T cells. Middle & right graph was the CD8+ and CD4+ TEff/EM cells, respectively.
(D-E) CD8+ and CD4+ T cells population in the tumor microenvironment, repesctively. Error bars indicate SEM for tumor
growth curves and SD for all other graphs. N = 3-4 mice per groups. *P < 0.05 and **P<0.01. 
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The reactivation ex vivo, of the tumor-draining lymph node and the spleen, was done to assess 
the T cell immune response after vaccinations. Although no significant differences in IFN?+ or 
TNF?+IFN?+ CD8+ T cells in the TdLN were observed between treatment groups (Fig 4.2.A, left & 
middle), a trend towards an increased activation was detected when mice were vaccinated 4 times. 
The same trends between treatments were observed by flow cytometry and by ELISA for IFN? 
expression (Fig 4.2.A, right). In the spleen, the percentage of TNF?+IFN?+ CD8+ (Fig.4.2.B, left) 
and CD4+ T cells (Fig.4.2.B, middle) were similar between the two vaccination groups and both 
were increased compared to irradiation only. As in the TdLN, IFN? secretion, assessed by ELISA, 
seemed to be increased in the 4x10?g CpG-B group compared to the 2x20?g CpG-B group (Fig 
4.2.B, right).  
 
 
Figure 4.2 A trend in favor of an increased immune activation was detected when mice were vaccinated. 2.5 x 105 B16-OVA 
tumor cells were inoculated in the right scapular dorsal skin before irradiating them with 15 Gy on day 7. The “ 2 x 20 μg CpG-B” 
group was vaccinated on days 7 and 14 whereas the “4 x 10 μg CpG-B” were injected on days 7, 10, 14 and 17. Finally, mice were 
sacrificed on day 19 post-inoculation to quantify the immune response. (A) Tumor-draining lymph node restimulation with 
SIINFEKL assessed by flow cytometry (Left & middle graph) and by ELISA (right graph). (B) T cells immune response in the 
spleen after reactivation ex vivo. Polyfunctional CD8+ and CD4+ T cells quantified by flow cytometry (left & middle graph) and IFN? 
production in the supernatant by ELISA (right). Error bars indicate SD for all graphs. N = 3-4 mice per groups. *P < 0.05. 
 
Overall, this experiment showed an enhance T cell activation when CpG-B vaccination was 
combined to radiotherapy and a small incline towards delay of the tumor growth when a single dose 
of CpG-B was used. In addition, the reactivation of the spleen and the TdLN showed no significant 
enhance immune activation when mice were vaccinated. 
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A decrease in tumor growth and increase in polyfunctional CD8+ T cells was observed 
when targeting the non-TdLN 
The next parameter tested was the variation in the T cell immune response when targeting the 
tumor-draining lymph node compared to a non-tumor draining lymph node. We hypothesized that 
the immune response would be increased when targeting the TdLN versus non-TdLN since tumor 
antigens, and activated APCs, would be drained to the TdLN. However, since the TdLN can be 
immunosuppressed, a dampening of the immune response can occur. This was tested by inoculating 
2.5 x 105 B16-OVA tumor cells in the right dorsal scapular skin before irradiating and vaccinating 
mice on day 7 post-inoculation (Fig.4.3.A). At day 18, a significant difference in tumor volume was 
observed when mice were vaccinated intradermally in the forelimb of the non-TdLN (30 ± 8 mm3) 
compared to the irradiated “only” group, 170 ± 131 mm3 (Fig.4.3.B). The decrease in tumor growth 
was not associated to an increase in SIINFEKL-specific CD8+ T cells in the spleen (Fig.4.3.C, left). 
The proportions of effector CD8+ and CD4+ T cells were increased for the vaccinated groups 
compared to irradiation only (Fig.4.3.C, middle & right) but no difference was observed between 
the two vaccine groups. The analysis of the immune infiltrate in the tumor microenvironment 
showed an increase in the frequency of CD8+ T cells (Fig.4.3.D, left) but no differences in CD4+ T 
cells (Fig.4.3.E, left). All three treatments showed no differences in CD69+ T cells and a decrease in 
PD-1+ CD8+ and CD4+, T cells when mice were vaccinated (Fig.4.3.D & E, middle & right). 
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Figure 4.3 Targeting the non-TdLN results in a more marked delay of tumor growth compared to the TdLN, without 
significant changes in T cell frequencies. 2.5 x 105 B16-OVA tumor cells were inoculated in the right scapular dorsal skin before 
irradiating them with 15 Gy on day 7 and 14. Both vaccinated groups received 20 μg CpG-B, per injection, intradermally in the hock 
draining, or not the TdLN. (A) Timeline and treatments. (B) Average, top, and individual, bottom, tumor growth. (C) T cell immune 
activation in the spleen. Left were the percentage of SIINFEKL-specific CD8+ T cells. Middle & right graph was the CD8+ and CD4+ 
TEff/EM cells, respectively. (D-E) CD8+ and CD4+ T cells population in the tumor microenvironment, respectively. Error bars indicate 
SEM for tumor growth curves and SD for all other graphs. N = 3-4 mice per groups. *P < 0.05 and **P<0.01.  
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CD8+ T cells from the spleen, TdLN and non-TdLN were reactivated ex-vivo with the MHC-I 
dominant OVA epitope, SIINFEKL. The TdLN did not show any difference in polyfunctional CD8+ 
T cells or IFN? secretion between all groups (Fig.3.4.A & B, left) and the non-TdLN had similar 
percentage in TNF?+IFN?+ CD8+ T cells (0.023 ± 0.02%), compared to the TdLN (0.03 ± 0.02%). 
However, we observed a significantly increased IFN? production in the non-tdLN in mice receiving 
the vaccine contralaterally to the tumor. This was explained by the fact that this specific lymph 
node was not targeted at all in the other two groups (Fig.4.4.A & B, middle). Finally, the spleen 
showed a significant increase in polyfunctional CD8+ T cells but no differences in IFN? secretion 
when targeting the non-TdLN (Fig.4.4.A & B, right). 
 
 
Figure 4.4 A significant increase in polyfunctional CD8+ T cells, in the spleen but not in the TdLN was observed when the 
non-TdLN was targeted. 2.5 x 105 B16-OVA tumor cells were inoculated in the right scapular dorsal skin before irradiating them 
with 15 Gy on day 7 and 14. Both vaccinated groups received 20 μg CpG-B, per injection, intradermally in the hock draining, or not 
the TdLN. (A-C) TNF?+IFN?+ CD8+ T cells after SIINFEKL reactivation (Top) and IFN? quantification (bottom), by ELISA, in the 
tumor-draining lymph node, the non-TdLN and the spleen. Error bars indicate SD for all graphs. N = 3-4 mice per groups. *P < 0.05 
and **P<0.01. 
 
In summary, a decrease in tumor growth was observed when targeting the non-TdLN, which 
was associated to a higher percentage of polyfunctional OVA-specific CD8+ T cells in the spleen.  
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Intradermal and intratumoral injection induced similar tumor growth and survival 
The final parameter tested was the injection site. Although the advantage of our adjuvanted-
particles was their capability to drain through the lymphatic system to reach the lymph node, we 
wanted to determine the difference in immune response and survival when vaccines were injected 
intradermally, in the forelimb draining to the TdLN compared to intratumorally. Although the 
previous experiment showed a stronger T cell activation when targeting the non-TdLN compared 
the TdLN, we decided to target to TdLN since both injection route would cause the adjuvants to 
drain to the same lymph node. When the tumor reached a size ranging between 50 and 150 mm3 
mice received a 15 Gy radiation dose localized to the tumor area and the first adjuvant vaccinations 
before waiting 3 more days to vaccinate a second time. Seven days after the first irradiation, a 
second cycle of treatment was performed using the same schedule as the first round (Fig.4.5.A). 
The dose of NP-CpG-B being rather low, it was thought important to vaccinate a second time 3 
days after to increase the immune response. The average tumor growth showed a slight decrease 
when mice were vaccinated compared to PBS-treated (Fig.4.5.B, top). In addition, two out of five 
mice in the intratumorally-administered group did not response to the first boost given on day 13. 
As observed in the tumor growth curve, the survival reflected no difference between the two 
vaccinated groups but was increased compared to the negative control (Fig.4.5.C). The proportion 
of SIINFEKL-specific CD8+ T cells was only slightly higher compared to the negative control and 
the percentage of CD44+CD62L- as well as CD25+ CD8+ T cell population was unchanged 
(Fig.4.5.D, top & bottom). 
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Figure 4.5 Intratumoral and intradermal NP-CpG-B injection have similar effects on tumor growth and mouse survival. 2.5 x 
105 B16-OVA tumor cells were inoculated in the right scapular dorsal skin before irradiating them with 15 Gy on day 10 and 17. 
Both vaccinated groups received 1 μg NP-CpG-B, per injection, intradermally or intratumoral. (A) Timeline and treatment groups. 
(B) Average (top) and individual tumor growth. (C) Survival curves. (D) Percentage of SIINFEKL-specific and CD25+ CD8+ T cells 
in the blood. Error bars indicate SEM for tumor growth curves and SD for all other graphs. N = 4-5 mice per groups. *P < 0.05 and 
**P<0.01. 
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Increased production of IL2 in the TdLN was detected when PS-MPLA & NP-CpG-
B were co-injected but similar tumor growth was observed for all vaccinated groups 
After determining the optimal injection route and vaccine schedule, PS-MPLA and NP-CpG-
B vaccine was tested, in combination with radiotherapy, to quantify the immune response. This 
combination was chosen based on the results obtained on the previous chapter. As a reminder, in 
vitro experiments showed strong synergistic effect in cytokines secretion after BMDC activation 
and, although, the immune response was similar to the single adjuvant, in vivo, a small decrease in 
tumor growth was detected. The PS-MPLA + PS-CL075 had similar in vitro results but the in vivo 
data did not induce as strong CD8+ T cells response compared to when NP-CpG-B was present in 
the treatment. Finally, PS-CL075 and NP-CpG-B combination did not show much synergistic effect 
in vitro and in vivo. For this experiment, only one cycle of irradiation and vaccination was 
performed in this chapter (Fig.4.6.A). The tumor growth curve did not show any differences 
between all vaccinated treatments but they were reduced compared to the non-vaccinated group 
(Fig.4.6.B). The staining of the spleen with SIINFEKL-specific CD8+ T cells did not show any 
significant difference between vaccinated mice and the negative control (Fig.4.6.C). The tumor 
microenvironment had an increased percentage of total CD8+ T cells, CD44+CD62L- CD8+ T cells 
for NP-CpG-B alone, or combined, and CD25+ CD8+ T cells was upregulated in all vaccinated 
groups similarly (Fig.4.6.D). The CD4+ T cell response, in the tumor microenvironment, also 
showed similar trends as the CD8+ T cells (Fig.4.6.E, left & middle). The percentage of CD4+ Treg 
was similar for all groups, with a slight increase for vaccinated mice (Fig.4.6.E, right).  
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Figure 4.6 Vaccination with single or combined adjuvants resulted in a delayed tumor growth and an increased T cell 
response. 2.5 x 105 B16-OVA tumor cells were inoculated in the right scapular dorsal skin before irradiating them with 15 Gy when 
tumor size reached 50-150 mm3. All vaccinated mice received two dose of vaccine, at day 10 and 13, by intradermal injection in the 
forelimb draining to the TdLN. (A) Timeline, treatment groups and adjuvant doses. (B) Average tumor growth. (C) SIINFEKL-
specific CD8+ T cells in the spleen, without restimulation. (D) CD8+ T cells immune response in the tumor microenvironment. (E) 
CD4+ T cells immune response in the tumor microenvironment. Error bars indicate SEM for tumor growth curves and SD for all 
other graphs. N = 4-6 mice per groups. *P < 0.05 and **P<0.01. 
 
The ex vivo CD8+ T cells reactivation for the TdLN showed no differences in the percentage 
of TNF?+IFN?+IL2+ positive cells (Fig.4.8.A, top left) but an increase in IL2 secretion was 
observed when both adjuvants were co-injected (277 ± 142 pg/mL) compared to all other 
treatments. A small trend in granzyme B production for all vaccinated groups was also detected 
(Fig.4.7.A, middle & bottom left). CD4+ T cells restimulation had an increase in triple positive cells 
when mice were vaccinated either with NP-CpG-B alone or combined (Fig.4.7.A, top right). In 
addition, a significant increase in IL2 and granzyme B secretion was observed when mice were 
vaccinated with PS-MPLA and NP-CpG-B and an even higher concentration of granzyme B was 
detected when NP-CpG-B alone was used to vaccinate the mice. Finally, no significant differences 
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were observed in cytokines secretion (Fig.4.7.B, middle & bottom) and polyfunctional cells 
(Fig.4.7.B, top) for all treatments when the spleen was reactivated with the SIINKEKL. 
 
 
 
Figure 4.7 NP-CPG-B, alone or in combination, induced a slightly higher T cell activation in the TdLN. 2.5 x 105 B16-OVA 
tumor cells were inoculated in the right scapular dorsal skin before irradiating them with 15 Gy when tumor size reached 50-150 
mm3. All vaccinated mice received two dose of vaccine, at day 10 and 13, by intradermal injection in the forelimb draining to the 
TdLN. (A) CD8+ and CD4+ T cells restimulation in the tumor-draining lymph node with SIINFEKL (left column) or OVA327-339 
(right column), respectively. Top graphs were TNF?+IFN?+IL2+ T cells. Middle and bottom graphs were IL2 and granzyme B 
quantification by ELISA, respectively. (B) CD8+ T cell reactivation in the spleen. Top was the percentage of polyfunctional CD8+ T 
cells after 6 h restimulation. Middle & bottom graphs, indicated the IL2 and granzyme B concentration in the supernatant after 4 days 
restimulation. Error bars indicate SD for all other graphs. N = 4-5 mice per groups. *P < 0.05 and **P<0.01 
 
 
Overall the strongest immune response was observed when either NP-CpG-B alone, or in 
combination with PS-MPLA, was used. In addition the production of IL2 was increased compared 
to the other treatments when both TLRs agonist were co-injected. 
 
84 
 
Co-injection of PS-MPLA & NP-CpG-B reduced tumor growth and increased 
overall survival compared to radiotherapy only or NP-CpG-B. 
Finally, an experiment was performed to determine if the adjuvant combination, together with 
tumor irradiation, increased the overall survival of tumor-bearing mice. The same vaccination 
schedule, and dose, as the previous experiment was used (Fig.4.9.A). Blood was sampled on day 
16, before the start of the second treatment cycle, to quantify the presence of SIINFEKL-specific 
CD8+ T cells as well as their activation. As observed in the previous experiments, the vaccinated 
mice had a delay in tumor growth with a stronger effect when both adjuvants were co-injected 
(Fig.4.8.B, top). Indeed, since the tumor grew slower, mice co-injected with both adjuvants had a 
delay in the tumor growth after the two rounds of radiotherapy (Fig.4.8.B, 3rd graph). The survival 
was increased by 5 and 17 days for the NP-CpG-B and PS-MPLA + NP-CpG-B, respectively, 
compared to irradiated mice only (Fig.4.8.C). A small increase in antigen-specific CD8+ T cells was 
detected when mice were only vaccinated with the TLR-9 agonist CpG-B (0.22 ± 0.05%) and the 
adjuvant combination had similar values (0.16 ± 0.04%) then the negative control, 0.16 ± 0.02% 
(Fig.4.8.D, top). On the other hand, PS-MPLA + NP-CpG-B injection induced a slightly higher 
percentage of CD25+ CD8 + T cells, compared to the two other groups (Fig.4.8.D, middle & bottom) 
but no differences in CD44+CD62L- CD8+ T cells. 
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Figure 4.8 Survival was increased when mice were co-injected with both adjuvants 2.5 x 105 B16-OVA tumor cells were 
inoculated in the right scapular dorsal skin before irradiating them with 15 Gy when tumor size reached 50-150 mm3. All vaccinated 
mice received two dose of vaccine, at day 10 and 13, by intradermal injection in the forelimb draining the tumor-draining lymph 
node. (A) Timeline, treatment groups and adjuvant doses. (B) Average and individual tumor growth. (C) Survival curve. (D) 
SIINFEKL-specific CD8+ T cells in the spleen, without restimulation and T cell immune activation. Top graph, SIINFEKL-specific 
CD8+ T cells. Middle & bottom graph were CD44+CD62L- and CD25+ CD8+ T cells, respectively. Error bars indicate SEM for tumor 
growth curves and SD for all other graphs. N = 4-6 mice per groups. *P < 0.05 and **P<0.01. 
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4.5. Discussion 
 
The main goal of this study was to determine the immune response and overall survival of 
B16-OVA tumor-bearing mice when radiotherapy was combined with an adjuvanted-
nanoparticulate vaccination. We hypothesized that since the immune priming occurred in the tumor-
draining lymph node after radiotherapy, the response would be increased if our vaccine would 
deliver TLR agonists to the same lymph node. In order to obtain to optimal immune response when 
combining adjuvant vaccination with ionizing radiation, several parameters were tested. 
 
The purpose of the first experiment was to determine if the combination of TLR agonist 
vaccination and radiotherapy enhanced the immune response compared to ionizing radiation only 
since most of the studies inject intratumorally the vaccine whereas we target the tumor-draining 
lymph node. The results demonstrated a clear increase in T cells immune response when mice were 
vaccinated, in addition to an increase of T cells infiltrate in the tumor microenvironment. In a 
second time we also tested two different vaccination schedule since the process by which APCs 
phagocytize cancer cells and drain to the lymph node is not instantaneous. We hypothesized that the 
immune response would be increased if mice received a second vaccination 3 days after the 1st 
adjuvant injection, due to a higher percentage of activated APCs in the lymph node. Surprisingly, 
following the two vaccination schedules the tumor growth was no different from the negative 
control, which was only irradiated (Fig.4.1.B). First of all the lack of differences with the negative 
control group could be due the time at which the first irradiation occurred. Indeed, the average 
tumor size for all three groups were between 5-30 mm3, which was considered rather small and, in 
addition, the irradiation used was considered ablative, thus the tumor growth delay could simply be 
due to the radiation and not because of the vaccination. The reasoning for using B16-OVA cell line 
was to be able to quantify the amount of SIINFEKL-specific CD8+ T cells but unfortunately, the 
percentage between all three treatments was not significantly different, although a small trend was 
detected when mice were vaccinated with 2 x 20 μg CpG-B compared to the other groups 
(Fig.4.1.C, left). Of course, since radiotherapy induces the release of a broad range of antigens, it 
was possible to have differences for other tumor antigens, such as TRP-2, gp100 or other 
neoantigens, which was not tested here. The adjuvant vaccination, independently of the schedule, 
increased the percentage of effector CD8+ T cells, in addition to having higher CD8+ T cells in the 
tumor microenvironment, which indicate an overall increased immune activation compared to the 
mice only irradiated (Fig.4.1.D, left). The small increase of PD-1+ T cells when mice were only 
irradiated, in addition to the decrease in cytokine secretion, after restimulation, would suggests an 
exhaustion of T cell or a lower immune activation. Indeed it is known that exhausted T cell express 
activation markers as well as PD-1 but induce less cytokine secretion 134, 135.  Although both vaccine 
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schedules induced similar response in the tumor microenvironment, the reactivation of specific 
peptide showed higher cytokine production, especially IFN?, when a vaccination boost was 
administered to the mice. The increased secretion observed during restimulation for the 4 x 10 μg 
CpG-B group could simply be due to the timing of the boost, which was 4 days before collecting 
the organs and so the increase was due to the activation caused by the vaccine rather than the 
reactivation itself. The slightly higher T cell activation observed for the 2 x 20 μg CpG-B compared 
to the other vaccine could be explain by the fact that the higher dose at an earlier time point was 
better at inducing an anti-tumor response. Overall, vaccinating mice with a TLR agonist enhanced 
the immune response compared to radiotherapy only and a small trend in increase activation was 
detected when for the group not receiving a boost. 
 
The second parameter tested was the choice of the lymph node to target. Indeed the most 
logical choice would be to target the tumor-draining lymph node since this is the location where 
tumor antigens and APCs would drain but there was a risk of it being immunosuppressive, which 
would dampen the immune response. The significant decrease in tumor growth when the non-TdLN 
was targeted was likely due to the initial size of the tumor (< 30 mm3) and the increased T cell 
response (as evidenced by the higher antigen-specific IFN? secretion in the spleen) compared to the 
other two treatments. Indeed both of these parameters were shown to be important at inducing a 
tumor growth reduction and immune response. Surprisingly, the reduced tumor size was not 
associated with an increased T cell population in the tumor compared to the negative control 
(Fig.4.3.C). The comparison of IFN? secretion in both lymph nodes indicated a small dampening of 
the immune response in the TdLN since it was decreased compared to the non-TdLN. Finally, the 
absence of IFN? in the non-TdLN in the two other treatment groups (Fig.4.4.B, bottom) 
demonstrate that the activation of the immune system occurs only in the adjuvant targeted lymph 
node, which would be important to reduce the risk of toxicity due to systemic activation as well as 
autoimmune disease. Indeed radiotherapy will induce the release of not only tumor antigens but also 
self-antigens, thus potentially activating the immune response in the lymph node against all of 
them. We hypothesized that if the activation happened in only a specific organ and not the entire 
system, the risk of adverse effect would be decreased. Overall, although results showed a decreased 
tumor growth and increased immune response, when targeting the non-TdLN, these experiments 
should be repeated with a later irradiation starting point to reduce the effect induced by radiotherapy 
in addition to using NP-CpG-B as vaccine.  
 
The last parameter tested was the injection site. As discussed in the introduction, most of the 
TLR agonist treatments currently tested in combination with radiotherapy are, for the most part, 
injected intratumorally. We were interested in comparing both injection routes to determine if one 
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was preferred to the other in term of T cell response when using nanocarriers to deliver the 
adjuvant. In general, mice vaccinated, independently from the injection site, showed a reduced 
tumor growth in addition to increased survival compared to irradiated only (Fig.4.5.B & C). 2 out of 
5 mice in the intratumoral injection groups did not responded after the first boost administered 
because, not only their size were close to the limit (700 mm3), the tumor ulcerated, thus preventing 
the second vaccination to be effective (Fig.4.5.B, 3rd graph). In addition due to the multiple 
vaccination (4x) and the technique used to irradiate mice, most tumors ulcerated at one point and if 
the vaccine was administered intratumorally, part of the injection was lost. As observed in the 
previous experiments, a trend was observed in the proportion of SIINFEKL-specific CD8+ T cells 
(Fig.4.5.C, top) and no difference in percentage (data not shown) of T cells, or activation 
(Fig.4.5.C, middle & bottom), were detected in the blood. Overall, the two different injection sites 
did not modify of the T cell immune response or the survival but due to the risk of losing the 
vaccination efficacy due to tumor ulceration, it was considered safer to inject mice intradermally in 
the forelimb draining to the TdLN for the following experiments. 
 
The induction of the immune response was quantified after combining radiotherapy with PS-
MPLA + NP-CpG-B adjuvant vaccination. All vaccinations tested decreased the tumor growth, 
similarly, but the tumor microenvironment had an increase in CD8+ and CD4+ T cells when mice 
were vaccinated with NP-CpG-B alone or in combination. In addition, the same vaccine induced a 
trend in increase CD44+CD62L- T cells, which suggested higher immune activation. Unfortunately, 
most of the CD4+ T cells present in the tumor were regulatory cells, which is known to induce an 
immunosuppressive environment, but the difference between vaccinated and the negative control 
were small, indicating no strong increase in suppression when the vaccination was added to the 
treatment. The increase in IL2 secretion after CD8+ or CD4+ T cell reactivation in the TdLN when 
both adjuvants were co-injected indicate a strong immune activation. This cytokine induces not 
only the activation and proliferation of CD8+ T cell, it also activates NK cells, which are important 
for a strong anti-tumor 136. It has been demonstrated that CD4+ T cells can also be cytotoxic and 
secrete granzyme B after recognition of the MHC-II antigen 137. The expression of granzyme B in 
CD4+ T cells restimulation condition was caused by an increase of secretion in IL2. Indeed it was 
shown that IL2 induced the expression of granzyme B, as well as perforin 138. Overall the co-
injection of PS-MPLA with NP-CpG-B, as well as NP-CpG-B to a lesser extent, induced a stronger 
immune response in the tumor-draining lymph node, which translated in an increase percentage in 
CD8+ or CD4+ T cells populations. The survival experiment with NP-CpG-B, with or without PS-
MPLA, demonstrated a strong reduction in tumor growth when mice were vaccinated with both 
adjuvants, which increased the survival of mice compared to the negative control group. Some 
studies had shown that an antibody response was able to reduce tumor growth but unfortunately, no 
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OVA-specific antibodies where detected in any of the treatment tested (data not shown). The exact 
mechanism by which the adjuvant combination induced a reduce tumor growth was not yet found 
but the increase in IL2 secretion in the tumor draining lymph node could be an reasonable option 
since it not only induce the activation of CD8+ T cells, it also activated NK cells. 
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Chapter 5 
5.  
Conclusion, Implication and Future prospect 
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5.1. Conclusion 
 
The purpose of this thesis was to develop a nano-adjuvant vaccine, which will target the tumor-
draining lymph node (TdLN), and evaluate its efficacy in melanoma, alone or in combination with 
radiotherapy. 
 
We have started this project by synthesizing the different components of the two nanocarriers, 
previously developed in our laboratory, and characterizing the loading of the different Toll-like 
receptors (TLRs) agonists on either of them. The adjuvants MPLA and CL075 were successfully 
encapsulated in polymersomes (PSs) whereas CpG-B was conjugated onto nanoparticles (NPs). A 
small decrease in dendritic cells (DCs) activation, in vitro, was observed when MPLA was loaded 
in polymersomes compared to the free adjuvant whereas no difference was detected for PS-CL075 
or NP-CpG-B compared to their free counterpart. Finally, we have also demonstrated that both 
particulates are internalized by DCs through macropinocytosis. 
 
Once we had characterized the different nano-adjuvants, we determined if synergistic effect 
could be detected when combining them together using a combinatorial approach. A strong increase 
in pro-inflammatory cytokine (IL2p70, TNF? and IL6) was observed when PS-MPLA was 
incubated with either PS-CL075 or NP-CpG-B with DCs, in vitro. In addition, it appeared that the 
highest dose tested induced exhaustion of the cells through the secretion of IL10. The third adjuvant 
combination, PS-CL075 and NP-CpG-B, only induced a synergy for the secretion of TNF? but not 
the other cytokines. Afterwards, we verified if the results obtained on DCs would translate into an 
enhanced T cell activation, in vitro and in vivo. Overall small increases in activations were detected 
in proliferation or cytokine production, in vitro, but none were synergistic. All three nano-adjuvant 
combinations were tested in vivo in a B16-OVA implantable melanoma model and although they all 
induced similar T cell immune responses, only PS-MPLA and NP-CpG-B was able to delay the 
tumor growth compared to the single adjuvant. 
 
Finally, we studied the combination of radiotherapy with our adjuvant-nanoparticulate vaccine 
as well as different parameters for the vaccine injection, such as the injection route, the lymph node 
targeted and the vaccine schedule. Most of the ongoing clinical trials and studies combining 
radiotherapy with adjuvant vaccine administer the treatment intratumorally and so we wanted to 
determine if the immune system could also be enhanced when injecting intradermally to target the 
tumor-draining lymph node. We have demonstrated an enhance T cell response when adjuvants 
were injected intradermally compared to ionizing radiation only. In addition, intradermal or 
intratumoral administration of NP-CpG-B induced similar tumor growth and survival. The 
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administration of PS-MPLA + NP-CpG-B, in combination with 15 Gy radiotherapy increased 
significantly the survival compared to NP-CpG-B vaccination or ionizing radiation only. 
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5.2. Implication and future directions 
Development of an adjuvanted-cancer vaccine 
One of the major goals of this thesis was to develop a cancer vaccine composed only of 
adjuvants, which were delivered to the tumor-draining lymph node thanks to the different particles 
produced in our laboratory. A majority of the studies published with these nanocarriers have used 
CpG-B as the adjuvants without testing other TLR agonist. Here we were able to produce, in 
addition to NP-CpG-B, two other nano-adjuvants, PS-MPLA and PS-CL075. In addition, the 
combination of the different adjuvants induced an enhanced DCs activation, in vitro. This research 
showed that although the adjuvants were on different particles, synergistic effect could still be 
observed in vitro. Indeed, most of the studies combining different TLRs agonists deliver them all on 
the same carrier, and so doses of each TLR cannot be varied. In our case, different doses could be 
used for the vaccine, making it a much more flexible and tunable approach. In addition, if someone 
would like to add another nano-adjuvant or antigen to our vaccine, it would be easy to do so without 
having to modify the pre-existing components of the vaccines. 
 
Although synergistic effects were detected for the combination of PS-MPLA with PS-CL075 or 
NP-CpG-B, when activating BMDCs in vitro, it did not translate in strong differences in T cells 
activation. In addition, some of the doses tested induced the production of IL10, indicating an 
overstimulation and exhaustion of DCs 139. A solution for this issue would be to decrease the 
incubation time in order to quantify cytokines secretion at an earlier stage of cell maturation, before 
it reaches exhaustion. In addition, only pro-inflammatory cytokines as well as IL10 have been 
quantified but MPLA is also supposed to induce the expression of type I IFN, which is known to 
initiate an anti-tumor response 140. A deeper understanding of the DCs activation in terms of 
cytokines and chemokines would help understanding the findings observed when testing the 
different nano-adjuvants combination in an orthotopical implantable melanoma model. Indeed, PS-
MPLA co-administered with NP-CpG-B decreased tumor growth but the T cell immune response 
was not different compared to the injection of only NP-CpG-B. It would also be interesting to 
assess the activation of other antigen-presenting cells in the lymph node in addition to natural killer 
cells and B cells which play a role in tumor growth. This could be done in vitro, thanks to co-
cultures, as well as in vivo. 
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Radiotherapy combination with adjuvanted vaccine 
Although radiotherapy was initially thought to only induce cell death and an 
immunosuppressive environment, it has since then been demonstrated that this treatment was able 
to induce an anti-tumor response depending on the irradiation dose, frequency and the type of 
cancer. Since radiotherapy is one of the first-line of treatment for many cancers, several clinical 
trials are testing the efficacy of adding intratumoral injection of adjuvants to it. In addition, it has 
been reported that following radiotherapy, the priming of the immune system occurs in the tumor-
draining lymph node 141. The advantage of combining our nano-adjuvant vaccine with radiotherapy 
was to take advantage of the targeting properties of the carriers for the tumor-draining lymph node 
to enhance the immune response taking place due to radiotherapy. In addition, several immune 
cells, as well as endothelial, are radiosensitive, and so rather than activating the immune system in 
the tumor microenvironment, which reduces the immune response within it, the lymph node 
immune population is not affected by the treatment. Finally, the induction of immunogenic cell 
death of cancerous cells will release a broad range of antigens, tumor-associate and tumor-specific, 
which in turn will educate the immune system against a broad range of molecules decreasing the 
chance of tumor evasions 142. 
 
Overall, we were able to enhance the immune response when both treatments were used and 
even increase survival when PS-MPLA + NP-CpG-B was used compared to only radiotherapy. We 
had previously shown that the immunosuppressive environment in the lymph node could be 
overturned into a more immunopermissive state when NP-CpG-B was administered 63. It would be 
interesting to quantify the immune suppression in the TdLN after radiotherapy by itself and how it 
changes after the different vaccination were administered. In addition, the response of other 
immune cells, such as natural killers (NK), NK T cells and macrophages should be assessed since 
we did not see clear differences in the T cell immune activation between the different vaccinations. 
 
An increasing number of studies show the advantage of combining different cancer treatments 
in order to fight the disease from all possible sides, and our approach has the advantage of being 
easily tunable and versatile depending on the vaccine requirement. Furthermore, our treatment 
targets the tumor-draining lymph node rather than the tumor directly, which when combined to 
radiotherapy is an important aspect due to the radiosensitivity of certain cells. One characteristic 
that our vaccine does not take into account is the immunosuppressive microenvironment generated 
by the tumor, which is a known mechanism for tumor evasion. Therefore, it would be important to 
assess how the tumor and the tumor-draining lymph node environments are modified after 
radiotherapy and vaccination, to further improve our treatment. 
  
96 
 
References 
 
1 World Health Organization. Cancer: Key facts. www.who.int/en/news-room/fact-
sheets/detail/cancer (2018). Available at: (Accessed: 20 May 2018) 
2 National Health Institute of the USA. Cancer Facts & Figures 2018. 1–76 (2018).  ti l lt  tit t   t  .  t   i  .  . 
3 Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nat Rev Cancer 6, 449–
458 (2006). 
4 Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. cell, 100(1), 57-70. 
5 Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The immunobiology of cancer 
immunosurveillance and immunoediting. Immunity, 21(2), 137-148. 
6 Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression 
and metastasis. Nature medicine, 19(11), 1423. 
7 Teng, M. W., Galon, J., Fridman, W. H., & Smyth, M. J. (2015). From mice to humans: 
developments in cancer immunoediting. The Journal of clinical investigation, 125(9), 
3338-3346. 
8 Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014). New insights into 
cancer immunoediting and its three component phases—elimination, equilibrium and 
escape. Current opinion in immunology, 27, 16-25. 
9  Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014). Immune-based mechanisms 
of cytotoxic chemotherapy: implications for the design of novel and rationale-based 
combined treatments against cancer. Cell death and differentiation, 21(1), 15. 
10 Chen, G., & Emens, L. A. (2013). Chemoimmunotherapy: reengineering tumor immunity. 
Cancer Immunology, Immunotherapy, 62(2), 203-216. 
11 Deloch, L., Derer, A., Hartmann, J., Frey, B., Fietkau, R., & Gaipl, U. S. (2016). Modern 
radiotherapy concepts and the impact of radiation on immune activation. Frontiers in 
oncology, 6, 141. 
12 Formenti, S. C., & Demaria, S. (2013). Combining radiotherapy and cancer 
immunotherapy: a paradigm shift. JNCI: Journal of the National Cancer Institute, 105(4), 
256-265. 
13 Koury, J., Lucero, M., Cato, C., Chang, L., Geiger, J., Henry, D., ... & Tran, A. (2018). 
Immunotherapies: Exploiting the Immune System for Cancer Treatment. Journal of 
immunology research, 2018. 
14 Rosenberg, S. A. (2014). Decade in review—Cancer immunotherapy: Entering the 
mainstream of cancer treatment. Nature Reviews Clinical Oncology, 11(11), 630 
15 Palucka, K., & Banchereau, J. (2013). Dendritic-cell-based therapeutic cancer vaccines. 
Immunity, 39(1), 38-48. 
16 ?????????? ???????????????? ??? ???????? ?????????? ??????????????? ???? ????? ????? ????
????????????????????????Molecular oncology, 9(10), 1994-2018. 
17 Pierce, R. H., Campbell, J. S., Pai, S. I., Brody, J. D., & Kohrt, H. E. (2015). In-situ tumor 
vaccination: bringing the fight to the tumor. Human vaccines & immunotherapeutics, 
11(8), 1901-1909. 
18 Hammerich, L., Binder, A., & Brody, J. D. (2015). In situ vaccination: Cancer 
?????????????? ????? ????????????? ???? ?????????????Molecular oncology, 9(10), 1966-
1981. 
19 Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2017). Advances in personalized 
cancer immunotherapy. Breast Cancer, 24(1), 16-24. 
20 Zhang, X., Sharma, P. K., Goedegebuure, S. P., & Gillanders, W. E. (2017). Personalized 
cancer vaccines: Targeting the cancer mutanome. Vaccine, 35(7), 1094-1100. 
21 Yang, Y. (2015). Cancer immunotherapy: harnessing the immune system to battle cancer. 
The Journal of clinical investigation, 125(9), 3335-3337. 
22 Ilyas, S., & Yang, J. C. (2015). Landscape of tumor antigens in T cell immunotherapy. The 
Journal of Immunology, 195(11), 5117-5122. 
97 
 
 
23 Coulie, P. G., Van den Eynde, B. J., Van Der Bruggen, P., & Boon, T. (2014). Tumour 
antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature 
Reviews Cancer, 14(2), 135. 
24 Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., ... & Wölfel, T. 
(2005). The response of autologous T cells to a human melanoma is dominated by mutated 
neoantigens. Proceedings of the National Academy of Sciences of the United States of 
America, 102(44), 16013-16018. 
25 Baitsch, L., Fuertes-Marraco, S. A., Legat, A., Meyer, C., & Speiser, D. E. (2012). The 
three main stumbling blocks for anticancer T cells. Trends in immunology, 33(7), 364-372. 
26 Chiang, C. L. L., Coukos, G., & Kandalaft, L. E. (2015). Whole tumor antigen vaccines: 
???????????????Vaccines, 3(2), 344-372. 
27 Spiotto, M., Fu, Y. X., & Weichselbaum, R. R. (2016). The intersection of radiotherapy 
and immunotherapy: mechanisms and clinical implications. Science immunology, 1(3). 
28 Chacon, J. A., Schutsky, K., & Powell, D. J. (2016). The impact of chemotherapy, 
radiation and epigenetic modifiers in cancer cell expression of immune inhibitory and 
stimulatory molecules and anti-tumor efficacy. Vaccines, 4(4), 43. 
29 Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., ... & 
Martins, I. (2013). Anticancer chemotherapy-induced intratumoral recruitment and 
differentiation of antigen-presenting cells. Immunity, 38(4), 729-741. 
30 Benvenuti, F. (2016). The dendritic cell synapse: a life dedicated to T cell activation. 
Frontiers in immunology, 7, 70. 
31 Thaiss, C. A., Semmling, V., Franken, L., Wagner, H., & Kurts, C. (2011). Chemokines: a 
new dendritic cell signal for T cell activation. Frontiers in immunology, 2, 31. 
32 Malissen, B., Grégoire, C., Malissen, M., & Roncagalli, R. (2014). Integrative biology of T 
cell activation. Nature immunology, 15(9), 790. 
33 Lizée, G., Overwijk, W. W., Radvanyi, L., Gao, J., Sharma, P., & Hwu, P. (2013). 
Harnessing the power of the immune system to target cancer. Annual review of medicine, 
64, 71-90. 
34 Palm, N. W., & Medzhitov, R. (2009). Pattern recognition receptors and control of 
adaptive immunity. Immunological reviews, 227(1), 221-233. 
35 Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., ... & 
Storkus, W. J. (2002). Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T cell 
responses against MAGE-6 in HLA-DRB10401+ patients with renal cell carcinoma or 
melanoma. Journal of Experimental Medicine, 196(5), 619-628. 
36 ????????? ??? ???? ?? ????????? ??? ???????? ????????? ??????????? ???? ?????? ????? ?????? ???
immunity and vaccine development. Clinical & translational immunology, 5(5). 
37 Ammi, R., De Waele, J., Willemen, Y., Van Brussel, I., Schrijvers, D. M., Lion, E., & 
Smits, E. L. (2015). Poly (I: C) as cancer vaccine adjuvant: knocking on the door of 
medical breakthroughs. Pharmacology & therapeutics, 146, 120-131. 
38 Einstein, M. H., Baron, M., Levin, M. J., Chatterjee, A., Edwards, R. P., Zepp, F., ... & 
Dubin, G. (2009). Comparison of the immunogenicity and safety of Cervarix™ and 
Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 
18–45 years. Human vaccines, 5(10), 705-719. 
39 Neidhart, J., Allen, K. O., Barlow, D. L., Carpenter, M., Shaw, D. R., Triozzi, P. L., & 
Conry, R. M. (2004). Immunization of colorectal cancer patients with recombinant 
baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in 
liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. 
Vaccine, 22(5-6), 773-780. 
40 Awasthi, S. (2014). Toll-like receptor-4 modulation for cancer immunotherapy. Frontiers 
in immunology, 5, 328. 
41 Narayan, R., Nguyen, H., Bentow, J. J., Moy, L., Lee, D. K., Greger, S., ... & Konishi, T. 
(2012). Immunomodulation by imiquimod in patients with high-risk primary melanoma. 
Journal of Investigative Dermatology, 132(1), 163-169. 
98 
 
 
42 Pashenkov, M., Goëss, G., Wagner, C., Hörmann, M., Jandl, T., Moser, A., ... & 
Tantcheva-Poor, I. (2006). Phase II trial of a Toll-like receptor 9–activating 
oligonucleotide in patients with metastatic melanoma. Journal of Clinical Oncology, 
24(36), 5716-5724. 
43 Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., & Klinman, D. M. (2011). CpG DNA as a 
vaccine adjuvant. Expert review of vaccines, 10(4), 499-511. 
44 Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, 
N. A., ... & Green, S. J. (2007). Clinical activity and immune modulation in cancer patients 
treated with CP-870,893, a novel CD40 agonist monoclonal antibody. Journal of Clinical 
Oncology, 25(7), 876-883. 
45 Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., 
Treisman, J., ... & Kendra, K. L. (2011). gp100 peptide vaccine and interleukin-2 in 
patients with advanced melanoma. New England Journal of Medicine, 364(22), 2119-
2127. 
46 Huckriede, A., Bungener, L., Stegmann, T., Daemen, T., Medema, J., Palache, A. M., & 
Wilschut, J. (2005). The virosome concept for influenza vaccines. Vaccine, 23, S26-S38. 
47 Swartz, M. A. (2001). The physiology of the lymphatic system. Advanced drug delivery 
reviews, 50(1-2), 3-20. 
48 Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A., & Swartz, M. A. (2006). In 
vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) 
nanoparticles. Journal of Controlled Release, 112(1), 26-34. 
49 Hauert, S., & Bhatia, S. N. (2014). Mechanisms of cooperation in cancer nanomedicine: 
towards systems nanotechnology. Trends in biotechnology, 32(9), 448-455. 
50 Adjei, I. M., Sharma, B., & Labhasetwar, V. (2014). Nanoparticles: cellular uptake and 
cytotoxicity. In Nanomaterial (pp. 73-91). Springer, Dordrecht. 
51 Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., 
... & Mahmoudi, M. (2017). Cellular uptake of nanoparticles: journey inside the cell. 
Chemical Society Reviews, 46(14), 4218-4244. 
52 Petros, R. A., & DeSimone, J. M. (2010). Strategies in the design of nanoparticles for 
therapeutic applications. Nature reviews Drug discovery, 9(8), 615. 
53 Orth, M., Lauber, K., Niyazi, M., Friedl, A. A., Li, M., Maihöfer, C., ... & Belka, C. 
(2014). Current concepts in clinical radiation oncology. Radiation and environmental 
biophysics, 53(1), 1-29. 
54 Prasanna, A., Ahmed, M. M., Mohiuddin, M., & Coleman, C. N. (2014). Exploiting 
sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy. 
Journal of thoracic disease, 6(4), 287. 
55 Galluzzi, L., Kepp, O., & Kroemer, G. (2013). Immunogenic cell death in radiation 
therapy. 
56 Golden, E. B., & Apetoh, L. (2015, January). Radiotherapy and immunogenic cell death. 
In Seminars in radiation oncology (Vol. 25, No. 1, pp. 11-17). Elsevier. 
57 Perez, C. A., Fu, A., Onishko, H., Hallahan, D. E., & Geng, L. (2009). Radiation induces 
an antitumour immune response to mouse melanoma. International journal of radiation 
biology, 85(12), 1126-1136. 
58 Cummings, R. J., Gerber, S. A., Judge, J. L., Ryan, J. L., Pentland, A. P., & Lord, E. M. 
(2012). Exposure to ionizing radiation induces the migration of cutaneous dendritic cells 
by a CCR7-dependent mechanism. The Journal of Immunology, 189(9), 4247-4257. 
59 Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., ... & Weichselbaum, R. 
R. (2009). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: 
changing strategies for cancer treatment. Blood, 114(3), 589-595. 
60 Gameiro, S. R., Jammed, M. L., Wattenberg, M. M., Tsang, K. Y., Ferrone, S., & Hodge, 
J. W. (2014). Radiation-induced immunogenic modulation of tumor enhances antigen 
processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget, 
5(2), 403. 
99 
 
 
61 Van Der Vlies, A. J., O’Neil, C. P., Hasegawa, U., Hammond, N., & Hubbell, J. A. (2010). 
Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing 
small molecules, peptides, and proteins. Bioconjugate chemistry, 21(4), 653-662. 
62 Thomas, S. N., Vokali, E., Lund, A. W., Hubbell, J. A., & Swartz, M. A. (2014). Targeting 
the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor 
immune response. Biomaterials, 35(2), 814-824. 
63 Jeanbart, L., Ballester, M., De Titta, A., Corthésy, P., Romero, P., Hubbell, J. A., & 
Swartz, M. A. (2014). Enhancing efficacy of anticancer vaccines by targeted delivery to 
tumor-draining lymph nodes. Cancer immunology research, 2(5), 436-447. 
64 De Titta, A., Ballester, M., Julier, Z., Nembrini, C., Jeanbart, L., Van Der Vlies, A. J., ... & 
Hubbell, J. A. (2013). Nanoparticle conjugation of CpG enhances adjuvancy for cellular 
immunity and memory recall at low dose. Proceedings of the National Academy of 
Sciences, 110(49), 19902-19907 
65 Scott, E. A., Stano, A., Gillard, M., Maio-Liu, A. C., Swartz, M. A., & Hubbell, J. A. 
(2012). Dendritic cell activation and T cell priming with adjuvant-and antigen-loaded 
oxidation-sensitive polymersomes. Biomaterials, 33(26), 6211-6219. 
66 Stano, A., Scott, E. A., Dane, K. Y., Swartz, M. A., & Hubbell, J. A. (2013). Tunable T 
cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. 
Biomaterials, 34(17), 4339-4346. 
67 Bagchi, A., Herrup, E. A., Warren, H. S., Trigilio, J., Shin, H. S., Valentine, C., & 
Hellman, J. (2007). MyD88-dependent and MyD88-independent pathways in synergy, 
priming, and tolerance between TLR agonists. The Journal of Immunology, 178(2), 1164-
1171. 
68 Minor, P. D. (2015). Live attenuated vaccines: historical successes and current challenges. 
Virology, 479, 379-392. 
69 Draper, S. J., & Heeney, J. L. (2010). Viruses as vaccine vectors for infectious diseases 
and cancer. Nature reviews Microbiology, 8(1), 62. 
70 Karch, C. P., & Burkhard, P. (2016). Vaccine technologies: from whole organisms to 
rationally designed protein assemblies. Biochemical pharmacology, 120, 1-14. 
71 Kourtis, I. C., Hirosue, S., De Titta, A., Kontos, S., Stegmann, T., Hubbell, J. A., & 
Swartz, M. A. (2013). Peripherally administered nanoparticles target monocytic myeloid 
cells, secondary lymphoid organs and tumors in mice. PloS one, 8(4), e61646. 
72 Nembrini, C., Stano, A., Dane, K. Y., Ballester, M., Van Der Vlies, A. J., Marsland, B. J., 
... & Hubbell, J. A. (2011). Nanoparticle conjugation of antigen enhances cytotoxic T-cell 
responses in pulmonary vaccination. Proceedings of the National Academy of Sciences, 
108(44), E989-E997. 
73 Hirosue, S., Kourtis, I. C., van der Vlies, A. J., Hubbell, J. A., & Swartz, M. A. (2010). 
Antigen delivery to dendritic cells by poly (propylene sulfide) nanoparticles with disulfide 
conjugated peptides: Cross-presentation and T cell activation. Vaccine, 28(50), 7897-7906. 
74 Galan-Navarro, C., Rincon-Restrepo, M., Zimmer, G., Saphire, E. O., Hubbell, J. A., 
Hirosue, S., ... & Kunz, S. (2017). Oxidation-sensitive polymersomes as vaccine 
nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. 
Virology, 512, 161-171. 
75 Rincon-Restrepo, M., Mayer, A., Hauert, S., Bonner, D. K., Phelps, E. A., Hubbell, J. A., 
... & Hirosue, S. (2017). Vaccine nanocarriers: Coupling intracellular pathways and 
cellular biodistribution to control CD4 vs CD8 T cell responses. Biomaterials, 132, 48-58. 
76 Sato, Y., Goto, Y., Narita, N., & Hoon, D. S. (2009). Cancer cells expressing toll-like 
receptors and the tumor microenvironment. Cancer microenvironment, 2(1), 205-214. 
77 Salem, M. L., Díaz-Montero, C. M., Al-Khami, A. A., El-Naggar, S. A., Naga, O., 
Montero, A. J., ... & Cole, D. J. (2009). Recovery from cyclophosphamide-induced 
lymphopenia results in expansion of immature dendritic cells which can mediate enhanced 
prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 
agonist poly (I: C). The Journal of Immunology, 182(4), 2030-2040. 
100 
 
 
78 Mehrotra, S., Britten, C. D., Chin, S., Garrett-Mayer, E., Cloud, C. A., Li, M., ... & Paulos, 
C. M. (2017). Vaccination with poly (IC: LC) and peptide-pulsed autologous dendritic 
cells in patients with pancreatic cancer. Journal of hematology & oncology, 10(1), 82. 
79 Iribarren, K., Bloy, N., Buqué, A., Cremer, I., Eggermont, A., Fridman, W. H., ... & 
Kroemer, G. (2016). Trial Watch: Immunostimulation with Toll-like receptor agonists in 
cancer therapy. Oncoimmunology, 5(3), e1088631. 
80 Vaure, C., & Liu, Y. (2014). A comparative review of toll-like receptor 4 expression and 
functionality in different animal species. Frontiers in immunology, 5, 316. 
81 Romanowski, B., Schwarz, T. F., Ferguson, L. M., Peters, K., Dionne, M., Schulze, K., ... 
& Schuind, A. (2011). Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted 
vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: 
Results from a randomized study. Human vaccines, 7(12), 1374-1386. 
82 Schwarz, T. F., Huang, L. M., Medina, D. M. R., Valencia, A., Lin, T. Y., Behre, U., ... & 
Descamps, D. (2012). Four-year follow-up of the immunogenicity and safety of the HPV-
16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10–14 years. 
Journal of Adolescent Health, 50(2), 187-194. 
83 Drachenberg, K. J., Wheeler, A. W., Stuebner, P., & Horak, F. (2001). A well‐tolerated 
grass pollen‐specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, 
reduces allergic symptoms after only four preseasonal injections. Allergy, 56(6), 498-505. 
84 Boland, G., Beran, J., Lievens, M., Sasadeusz, J., Dentico, P., Nothdurft, H., ... & Van 
Hattum, J. (2004). Safety and immunogenicity profile of an experimental hepatitis B 
vaccine adjuvanted with AS04. Vaccine, 23(3), 316-320. 
85 Thoelen, S., De Clercq, N., & Tornieporth, N. (2001). A prophylactic hepatitis B vaccine 
with a novel adjuvant system. Vaccine, 19(17-19), 2400-2403. 
86 Cervantes, J. L., Weinerman, B., Basole, C., & Salazar, J. C. (2012). TLR8: the forgotten 
relative revindicated. Cellular & molecular immunology, 9(6), 434. 
87 Lu, C. C., Kuo, H. C., Wang, F. S., Jou, M. H., Lee, K. C., & Chuang, J. H. (2014). 
Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. International 
journal of molecular sciences, 16(1), 159-177. 
88 Scheiermann, J., & Klinman, D. M. (2014). Clinical evaluation of CpG oligonucleotides as 
adjuvants for vaccines targeting infectious diseases and cancer. Vaccine, 32(48), 6377-
6389. 
89 Hanagata, N. (2017). CpG oligodeoxynucleotide nanomedicines for the prophylaxis or 
treatment of cancers, infectious diseases, and allergies. International journal of 
nanomedicine, 12, 515. 
90 Liu, L., Yong, K. T., Roy, I., Law, W. C., Ye, L., Liu, J., ... & Prasad, P. N. (2012). 
Bioconjugated pluronic triblock-copolymer micelle-encapsulated quantum dots for 
targeted imaging of cancer: in vitro and in vivo studies. Theranostics, 2(7), 705. 
91 Rehor, A., Hubbell, J. A., & Tirelli, N. (2005). Oxidation-sensitive polymeric 
nanoparticles. Langmuir, 21(1), 411-417. 
92 Velluto, D., Demurtas, D., & Hubbell, J. A. (2008). PEG-b-PPS diblock copolymer 
aggregates for hydrophobic drug solubilization and release: cyclosporin A as an example. 
Molecular pharmaceutics, 5(4), 632-642. 
93 Lutz, M. B., Kukutsch, N., Ogilvie, A. L., Rößner, S., Koch, F., Romani, N., & Schuler, G. 
(1999). An advanced culture method for generating large quantities of highly pure 
dendritic cells from mouse bone marrow. Journal of immunological methods, 223(1), 77-
92. 
94 Han, H. D., Byeon, Y., Jang, J. H., Jeon, H. N., Kim, G. H., Kim, M. G., ... & Lee, Y. J. 
(2016). In vivo stepwise immunomodulation using chitosan nanoparticles as a platform 
nanotechnology for cancer immunotherapy. Scientific reports, 6, 38348. 
95 Hafner, A. M., Corthésy, B., Textor, M., & Merkle, H. P. (2016). Surface-assembled poly 
(I: C) on PEGylated PLGA microspheres as vaccine adjuvant: APC activation and 
bystander cell stimulation. International journal of pharmaceutics, 514(1), 176-188. 
101 
 
 
96 Wu, C. Y., Yang, H. Y., Monie, A., Ma, B., Tsai, H. H., Wu, T. C., & Hung, C. F. (2011). 
Intraperitoneal administration of poly (I: C) with polyethylenimine leads to significant 
antitumor immunity against murine ovarian tumors. Cancer Immunology, Immunotherapy, 
60(8), 1085-1096. 
97 Velluto, D., Thomas, S. N., Simeoni, E., Swartz, M. A., & Hubbell, J. A. (2011). PEG-b-
PPS-b-PEI micelles and PEG-b-PPS/PEG-b-PPS-b-PEI mixed micelles as non-viral 
vectors for plasmid DNA: tumor immunotoxicity in B16F10 melanoma. Biomaterials, 
32(36), 9839-9847. 
98 Vartak, A., & Sucheck, S. J. (2016). Recent advances in subunit vaccine carriers. 
Vaccines, 4(2), 12. 
99 Pulendran, B., & Ahmed, R. (2011). Immunological mechanisms of vaccination. Nature 
immunology, 12(6), 509. 
100 Petrovsky, N. (2015). Comparative safety of vaccine adjuvants: a summary of current 
evidence and future needs. Drug safety, 38(11), 1059-1074. 
101 Lei, C., Liu, P., Chen, B., Mao, Y., Engelmann, H., Shin, Y., ... & Hellstrom, K. E. (2010). 
Local release of highly loaded antibodies from functionalized nanoporous support for 
cancer immunotherapy. Journal of the American Chemical Society, 132(20), 6906-6907. 
102 Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017). Designer 
vaccine nanodiscs for personalized cancer immunotherapy. Nature materials, 16(4), 489. 
103 Zhang, Z., Tongchusak, S., Mizukami, Y., Kang, Y. J., Ioji, T., Touma, M., ... & Sasada, 
T. (2011). Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle 
mediated antigen delivery. Biomaterials, 32(14), 3666-3678. 
104 Xu, Z., Ramishetti, S., Tseng, Y. C., Guo, S., Wang, Y., & Huang, L. (2013). 
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent 
cytotoxic T-lymphocyte response against melanoma and its lung metastasis. Journal of 
Controlled Release, 172(1), 259-265. 
105 Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., ... & Jones, T. 
(2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a 
strategy for cancer therapy. Cancer cell, 25(6), 846-859. 
106 REED, Steven G., ORR, Mark T., et FOX, Christopher B. Key roles of adjuvants in 
modern vaccines. Nature medicine, 2013, vol. 19, no 12, p. 1597. 
107 Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., ... 
& Villinger, F. (2011). Programming the magnitude and persistence of antibody responses 
with innate immunity. Nature, 470(7335), 543.  
108 Fox, C. B., Sivananthan, S. J., Duthie, M. S., Vergara, J., Guderian, J. A., Moon, E., ... & 
Carter, D. (2014). A nanoliposome delivery system to synergistically trigger TLR4 AND 
TLR7. Journal of nanobiotechnology, 12(1), 17. 
109 Abhyankar, M. M., Noor, Z., Tomai, M. A., Elvecrog, J., Fox, C. B., & Petri Jr, W. A. 
(2017). Nanoformulation of synergistic TLR ligands to enhance vaccination against 
Entamoeba histolytica. Vaccine, 35(6), 916-922. 
110 Broggi, M. A., Schmaler, M., Lagarde, N., & Rossi, S. W. (2014). Isolation of murine 
lymph node stromal cells. Journal of visualized experiments: JoVE, (90). 
 111 Dowling, D. J., Scott, E. A., Scheid, A., Bergelson, I., Joshi, S., Pietrasanta, C., ... & Kats, 
D. (2017). Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of 
the live BCG vaccine and enhance neonatal innate and adaptive immune responses. Journal 
of Allergy and Clinical Immunology, 140(5), 1339-1350. 
112 Tan, R. S., Ho, B., Leung, B. P., & Ding, J. L. (2014). TLR cross-talk confers specificity to 
innate immunity. International reviews of immunology, 33(6), 443-453. 
113 Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., & Hymowitz, S. G. (2011). Regulation 
and functions of the IL-10 family of cytokines in inflammation and disease. Annual review 
of immunology, 29, 71-109. 
102 
 
 
114 Wilbers, R. H., Van Raaij, D. R., Westerhof, L. B., Bakker, J., Smant, G., & Schots, A. 
(2017). Re-evaluation of IL-10 signaling reveals novel insights on the contribution of the 
intracellular domain of the IL-10R2 chain. Plos One, 12(10), e0186317. 
115 Smith, L. K., Boukhaled, G. M., Condotta, S. A., Mazouz, S., Guthmiller, J. J., Vijay, R., 
... & Richer, M. J. (2018). Interleukin-10 Directly Inhibits CD8+ T Cell Function by 
Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. Immunity, 48(2), 299-
312. 
116 Cox, M. A., Kahan, S. M., & Zajac, A. J. (2013). Anti-viral CD8 T cells and the cytokines 
that they love. Virology, 435(1), 157-169. 
117 Trinchieri, G. (2007). Interleukin-10 production by effector T cells: Th1 cells show self 
control. Journal of Experimental Medicine, 204(2), 239-243. 
118 Kabelitz, D. (2007). Expression and function of Toll-like receptors in T lymphocytes. 
Current opinion in immunology, 19(1), 39-45. 
119 Kahan, S. M., Bakshi, R. K., Luther, R., Harrington, L. E., Hendrickson, R. C., Lefkowitz, 
E. J., … & Zajac, A. J. (2017). IL-2 producing and non-producing effector CD8 T cells 
phenotypically and transcriptionally coalesce to form memory subsets with similar 
protective properties. 
120 Shiao, S. L., & Coussens, L. M. (2010). The tumor-immune microenvironment and 
response to radiation therapy. Journal of mammary gland biology and neoplasia, 15(4), 
411-421. 
121 Friedman, E. J.. 2002. Immune modulation by ionizing radiation and its implications for 
cancer immunotherapy. Curr. Pharm. Design 8: 1765-1780 
122 Trowell, O. A. (1952). The sensitivity of lymphocytes to ionising radiation. The Journal of 
Pathology, 64(4), 687-704. 
123 Ciernik, I. F., Romero, P., Berzofsky, J. A., & Carbone, D. P. (1999). Ionizing radiation 
enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. International 
Journal of Radiation Oncology• Biology• Physics, 45(3), 735-741. 
124  Filatenkov, A., Baker, J., Mueller, A. M., Kenkel, J., Ahn, G. O., Dutt, S., ... & Shizuru, J. 
A. (2015). Ablative tumor radiation can change the tumor immune cell microenvironment 
to induce durable complete remissions. Clinical Cancer Research, 21(16), 3727-3739. 
125 Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. 
(2005). Local radiation therapy of B16 melanoma tumors increases the generation of tumor 
antigen-specific effector cells that traffic to the tumor. The Journal of Immunology, 
174(12), 7516-7523. 
126 Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, 
S. C., & Demaria, S. (2009). Fractionated but not single-dose radiotherapy induces an 
immune-mediated abscopal effect when combined with anti–CTLA-4 antibody. Clinical 
Cancer Research, 15(17), 5379-5388. 
127 Gerber, S. A., Sedlacek, A. L., Cron, K. R., Murphy, S. P., Frelinger, J. G., & Lord, E. M. 
(2013). IFN-? mediates the antitumor effects of radiation therapy in a murine colon tumor. 
The American journal of pathology, 182(6), 2345-2354. 
128 Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M. 
(2008). Radiation-induced IFN-? production within the tumor microenvironment 
influences antitumor immunity. The Journal of Immunology, 180(5), 3132-3139. 
129 Finkelstein, S. E., Rodriguez, F., Dunn, M., Farmello, M. J., Smilee, R., Janssen, W., ... & 
Torres-Roca, J. F. (2012). Serial assessment of lymphocytes and apoptosis in the prostate 
during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy, 
4(4), 373-382. 
130 Finkelstein, S. E., Iclozan, C., Bui, M. M., Cotter, M. J., Ramakrishnan, R., Ahmed, J., ... 
& Berman, C. (2012). Combination of external beam radiotherapy (EBRT) with 
intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue 
sarcoma patients. International Journal of Radiation Oncology• Biology• Physics, 82(2), 
924-932. 
103 
 
 
131 Chi, K. H., Liu, S. J., Li, C. P., Kuo, H. P., Wang, Y. S., Chao, Y., & Hsieh, S. L. (2005). 
Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic 
cell immunotherapy in refractory hepatoma. Journal of immunotherapy, 28(2), 129-135. 
132 Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., ... & 
Wapnir, I. (2010). In situ vaccination with a TLR9 agonist induces systemic lymphoma 
regression: a phase I/II study. Journal of clinical oncology, 28(28), 4324. 
133 Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., ... & 
Tibshirani, R. J. (2012). In situ vaccination against mycosis fungoides by intratumoral 
injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood, 119(2), 
355-363. 
134 Mognol, G. P., Spreafico, R., Wong, V., Scott-Browne, J. P., Togher, S., Hoffmann, A., ... 
& Trifari, S. (2017). Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating 
T cells. Proceedings of the National Academy of Sciences, 114(13), E2776-E2785. 
135 Jiang, Y., Li, Y., & Zhu, B. (2015). T-cell exhaustion in the tumor microenvironment. Cell 
death & disease, 6(6), e1792. 
136 Liao, W., Lin, J. X., & Leonard, W. J. (2013). Interleukin-2 at the crossroads of effector 
responses, tolerance, and immunotherapy. Immunity, 38(1), 13-25. 
137 Takeuchi, A., & Saito, T. (2017). CD4 CTL, a cytotoxic subset of CD4+ T cells, their 
differentiation and function. Frontiers in immunology, 8, 194. 
138 Janas, M. L., Groves, P., Kienzle, N., & Kelso, A. (2005). IL-2 regulates perforin and 
granzyme gene expression in CD8+ T cells independently of its effects on survival and 
proliferation. The Journal of Immunology, 175(12), 8003-8010. 
139 Kajino, K., Nakamura, I., Bamba, H., Sawai, T., & Ogasawara, K. (2007). Involvement of IL‐10 
in exhaustion of myeloid dendritic cells and rescue by CD40 stimulation. Immunology, 120(1), 28-
37. 
140 Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., ... 
& Murphy, K. M. (2011). Type I interferon is selectively required by dendritic cells for immune 
rejection of tumors. Journal of Experimental Medicine, jem-20101158. 
141 Herrera, F. G., Bourhis, J., & Coukos, G. (2017). Radiotherapy combination opportunities 
leveraging immunity for the next oncology practice. CA: a cancer journal for clinicians, 67(1), 65-
85. 
142 Neller, M. A., López, J. A., & Schmidt, C. W. (2008, October). Antigens for cancer 
immunotherapy. In Seminars in immunology (Vol. 20, No. 5,pp. 286-295). Academic Press. 
104 
 
Curriculum Vitae 
 
 
 
Education 
 Ecole Polytechnique Fédérale de Lausanne (EPFL) 
2014 – Present PhD in Chemistry and chemical Engineering 
 Research area in cancer vaccines and nanoparticles 
 Ecole Polytechnique Fédérale de Lausanne (EPFL) 
2012 – 2013 Master of Science MSc in molecular and biological chemistry 
 Project: “Hyaluronic acid decorated nanoparticle targeting lymphatic endothelium 
cells” 
2013 Laboratory project (EPFL, 2 d/week) 
 “Generation of photoswitchable peptides ligand by phage display” 
 
2009 – 2012 Bachelor of Science BSc in chemistry and chemical engineering 
 Lycée Denis-de-Rougemont, Neuchâtel 
2004 – 2008 Scientific Baccalaureat, specific option: Biology - Chemistry 
 Bilingual maturity English - French 
Teaching experience 
2016 Master Project Supervisor, Chemistry and Chemical Engineering, EPFL 
2014 – 2016 Teaching Assistant for Biochemistry course (BSc) in Life Sciences and 
Technology, EPFL  
2014 – 2016  Teaching Assistant for Biomaterial course (MSc) in Life Science and 
Technology, EPFL 
2015 – 2016 High School outreach: Immersion in Science 
2008 – 2016 Ice Skating Coach (Neuchâtel, 4 h/week) 
Sylvie Hauert  
2040 Rownham Hill Road 20/02/1989 
60451 New Lenox, IL, USA Swiss 
+1 773 358 0838 sylvie.hauert@gmail.com 
105 
 
Publications 
Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 
vs CD8 T cell responses. Rincon-Restrepo M.1, Mayer A.1, Hauert S., Bonner D. K., Phelps E. A., 
Hubbell J. A., Swartz M. A., Hirosue S. 
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in 
melanoma. Fankhauser M., Broggi M. A. S., Potin L., Bordry N., Jeanbart L., Lund A., Da Costa 
E., Hauert S., Rincon-Restrepo M., Tremblay C., Cabello E., Homicsko K., Michielin O., Hanahan 
D., Speiser D. E., Swartz M. A. 
Nanoparticle conjugation of human papillomavirus 16 E7-long peptides enhances therapeutic 
vaccination efficacy against well-established solid tumors in mice. Galliverti G., Tichet M., 
Domingos-Pereira S., Hauert S., Nardelli-Haefliger D., Swartz M. A., Wullschleger S. In 
preparation 
Skills 
Immunology Techniques : Flow cytometry, ELISA, Primary cell isolation, in vitro cultures 
Molecular biology : RNA extraction, cDNA synthesis, RT-PCR, western blot,        
protein and DNA electrophoresis 
Mouse in vivo techniques : Anesthesia, intraperitoneal and intradermal injections, 
immunization, tumor inoculation, localize irradiation 
Chemistry : Strong synthesis understanding and background 
Programming language : C, Matlab 
Software: Microsoft Office, ChemDraw, Adobe Illustrator, GraphPad 
Prism, FlowJo 
Language 
French :  Mother tongue 
English :  Second mother tongue 
 Obtention of the First Certificate in English (FCE) in 2007 
German :  High school understanding 
 
Interests 
 
Traveling, discover new cultures and plays all types of sports. 
